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Introduction and aims of the study. 
1-1. General introduction 
In 1698 Sir John Royer discribed for the first time the clinical entity of exercise-induced 
asthma (EIA).[1] In 1966 Heimlich et al introduced the name "exercise induced asthma".[2] In 
1984 Bierman et al confirmed the existence of an early asthmatic reaction (EAR) and late 
asthmatic reaction (LAR) after exercise challenge. [3] Now, exercise is considered as a common 
and potent trigger of bronchoconstriction in asthmatic patients [4]. 
The early fall in PEER or in FEV1 appears within ten minutes after exercise, reaches a 
maximum after 20-30 minutes and nonnally disappears within 1-3 hours.[3] The definition of 
EAR after exercise is, according to Anderson: the existence of a fall greater than 10% of the pre-
exercise value in PEER (peak expiratory flow rate) or in FEV1 (forced expiratory volume in one 
second) after exercise [5]. The results in this thesis are reported not according to Anderson's 
definition of EIA. There is no agreement in the medical literature whether the percentage of a 
PEER fall after an exercise challenge should be 10 or 20%. It depends on the spontaneous 
variability of the bronchial obstruction for the population studied. If a change in PEER S 10% is 
considered as relevant, spontaneous variability has to be < 10%. The EAR in this thesis is 
defined as a fall in PEER of greater than 20% compared to pre-exercise value. 
The late reaction can occur after recovery firom the early reaction and starts 3-12 hours 
after the exercise, decreases in severity 12 hours after challenge and has usually disappeared 
within 24 hours after challenge. The pattern of response is very similar to the pattern observed 
after allergen provocation. Considering the possibility of a LAR after exercise challenge one 
should consider the effect of stopping drugs on the course of pulmonary function during the 
day. The assessment of the course of pulmonary function during a control day seems for this 
reason particularly important to eliminish the diumal rhythm. 
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In this study the PEFR was assessed with the mini-Wright peak-flow meter to measure 
bronchial obstruction. It is a suitable instrument for recording the PEFR after an exercise 
challenge. The mini Wright peak flow meter is a reliable, pocket-sized, simple, cheap and 
robust instrument for following changes in ventilatory function, the measurements appeared to 
be good reproducible. [6,7] 
The investigations in this thesis firstly dealt with the problem which decrease in PEFR 
was the most useful in the definition of an EAR and LAR. 
1- 2. Controversies about the LAR after exercise challenge 
The controversy in the literature about the LAR to exercise is about whether or not late 
responses to exercise do exist and if so, what is their frequency. The first problem of analyzing 
this problem is the following: to which value should a fall in PEFR 3-13 hours after exercise be 
related to? Is this the pre-exercise value, or the value at corresponding clocktime on a control 
day, or the pre-exercise/predicted PEFR, or the pre-exercise/mean value on the control day, or 
perhaps another value? Is it to be expected that the LAR after exercise challenge can exist as a 
clinical entity or is it an aspecific epiphenomenon? The LAR however occurs after allergen 
inhalation and after metacholine provocation. When the LAR after exercise challenge occurs a 
consistent protocol for measurements of bronchial obstruction is necessary. 
The LAR after allergen provocation is a well known phenomenon which will be 
discussed briefly in 1-3. It is accompanied by an increased hyperreactivity to methacholine and 
histamine [8], this is not the case in the LAR after exercise challenge [8,9,10]. Thus both LAR 
after exercise challenge and LAR after allergen exposition must be regarded as distinct specific 
phenomena. 
When methacholine was inhaled in high concentrations to overcome the effect of 
ipratropiumbromide given before, a prolonged asthmatic response occurs after 5-12 hours 
which is not directly related to the height of the methacholine dose [11]. This prolonged 
response has to be considered as an extended EAR. This can be caused by a prolonged high 
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methacholine level in the blood because methacholine is only slowly hydrolyzed by 
acetylcholinesterase. [11]. Salbutamol, a beta2-sympathomimetic agent is capable of blocking 
this reaction. [11]. This is also the case in the LAR after exercise challenge. [3,12,13]. Boulet 
et al. demonstrated that asthmatic adults with a LAR after exercise challenge did not have a LAR 
after methacholine inhalation one week later. [10]. Thus if one could speak of a LAR after 
methacholine inhalation, this is distinct from the LAR after exercise challenge. Also in asthmatic 
children with a LAR after exercise challenge a LAR after acetylcholine exposition does not 
occur [14]. The arguable LAR after methacholine inhalation is also distinct from the LAR after 
allergen exposition [11]. The LAR after exercise challenge and methacholine provocation are 
not comparable as stimulating agents. The LAR after methacholine provocation is not a LAR but 
an extended EAR and is distinct from the LAR after exercise challenge. 
1-3. Mechanisms of the EAR and LAR after allergen inhalation and exercise challenge 
The EAR is responsible for bronchoconstriction which causes symptoms of dyspnoe in 
the patient. Vasodilatation, oedema, mediator release and smooth muscle contraction occur 
during the EAR after allergen inhalation. [IS, 16].This bronchoconstrictive response is 
mediated by the actions of preformed and newly generated inflammatory mediators released 
after the IgE-dependent activation of mast cells associated with the bronchial mucosa. [17] 
Besides mast cells other cells produce and release mediators, such as epithelial cells, alveolar 
macrophages, basophils, eosinophils and neutrophils. Bronchial hyperreactivity may increase 
during the EAR after allergen challenge. [18,19] The mechanisms of that increase in reactivity 
are not well understood but appear to be related to the airway inflammation after the release of 
mediators. 
The late fall in FEVI or PEFR after provocation with inhalation allergens is a well 
known phenomenon. The prevalence, mechanisms and treatment are more clarified than the 
LAR after exercise challenge. It is already well known that the LAR after allergen inhalation can 
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occur without a preceding EAR. [3,20,21]. Mediator release and inflammation are mentioned 
as factors which cause a LAR. [3]. During the LAR after allergen inhalation a thickening of 
airway mucosa is present which is the result of plasma exudation and cellular infiltration. [15, 
22]. 
Cells which are playing a role in the LAR after allergen exposition are : mastcells, 
alveolar macrophages, eosinophils, monocyts, neutrophils and thrombocytes. [8]. When the 
LAR after allergen exposure gradually disappears, the cellular infiltrate becomes more 
mononuclear instead of polymorfnuclear. 
The cellular events taking place during the LAR after allergen exposure are considered 
highly relevant to the pathogenesis of asthma. Broncho alveolar lavage (BAL) and studies of the 
cellular changes during this response have demonstrated the presence of inflammatory cells 
(e.g. eosinophils and neutrophils), indicating active migration of these cells into the bronchial 
lumen. Inflammatory cells may be mobilized by chemotactic agents of protein or lipid-nature 
such as neutrophil chemotactic agent (NCA), serum eosinophilic cationic protein (s-ECP), 
complement fragments such as C5a, leucotriene B4 and platelet-activating factor (PAF). 
The LAR after allergen inhalation is followed by an increase in bronchial 
hyperreactivity. [18] 
In asthmatics heavy exercise over several minutes may be followed by an increase in 
airway resistance. Airway cooling, water loss and mediator release are important factors in the 
mechanisms of the EAR.[23] A neutrophil chemotactic agent (NCA) of high molecular weight 
can be detected in the bloodstream of 75% of asthmatic subjects during the EAR after exercise 
challenge. The evidence for the mast cell as the source of NCA is circumstantial, and NCA is 
also released by mononuclear cells through an IgE-dependent mechanism. However, the release 
of NCA is paralleled by the release of other mast cell-derived mediators. [24,25] The intensity 
of the exercise challenge partly determines the severity of the EAR. Moreover, the EAR after 
exercise challenge has been observed even after inhalation of water-saturated air of body 
temperature without heat or water loss [23,26, 27]. Another mechanism may perhaps play a 
role in the underlying pathofysiological event. After exercise 40-50% of asthmatic individuals 
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with an EAR after exercise challenge will be less responsive to an identical exercise task 
performed within one hour. This is known as the refractory period. [12, 20, 28] Airway 
inflammation due to the influx of inflammatory cells and the subsequent mediator release is 
causing narrowing of the airway lumen. [9, 29] Airway inflammation may disrupt epithelial 
integrity, increase mucosal permeability, and contribute to the smooth muscle 
hyperresponsiveness. This sequence of events may explain the increased bronchial 
hyperresponsiveness to histamine or metacholine. [30] Subjects who are hyperreactive to one 
stimulus also show a greater response to other constrictor stimuli such as exercise. [31] 
Controversial data are present about the LAR after exercise challenge. [32, 33]. 
According to some authors there would be no difference in clinical symptoms, daily FEVI 
variation, degree of hyperreactivity in patients with an isolated EAR от in patients with an EAR 
and LAR (dual responders) after exercise challenge. [11, 21, 34]. However, according to 
others the LAR after exercise challenge would occur more often in patients with a severe EAR 
(decrease in FEVI of S 40% of predicted value) and an incomplete recovery to baseline during 
the first 3 hours after exercise. [3]. The severity of the EAR and of the LAR in dual responders 
are significantly correlated. [34] According to other authors the EAR and LAR are not correlated 
and it is suggested that the LAR appears without a preceding EAR [35,36]. In patients with an 
isolated EAR or isolated LAR, there is no difference in age, sex, atopy, basal FEVI and 
РС20-П0] The severity of the LAR after exercise challenge is related to the severity and 
duration of the exercise challenge and is also related to the bronchial hyperreactivity of the 
patients airways.[37] The same goes for the EAR. The common opinion is that the LAR after 
exercise challenge is less severe than the EAR. [3] but according to a minority of authors the 
LAR after exercise challenge in some patients may be more severe than the EAR. [10, 11] 
However, the LAR after exercise challenge is less frequent and less severe in comparison with 
the LAR after allergen inhalation. [3]. Both types of LARs are varying in time of occurrence 
and in duration after exposure to the stimulus. [3]. 
The LAR after exercise challenge still occurs when the EAR after exercise challenge is 
inhibited by inhalation of warm humid air, which prevents mediator release. It is found that the 
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LAR after exercise challenge may occur independently from EAR after exercise challenge [35, 
36]. Mediators, released during the EAR would serve as a base for airway obstruction for the 
LAR. [3]. The late increase in NCA (neutrophil chemotactic agent) after exercise challenge is 
less in comparison with allergen inhalation. [21]. In addition it is relevant to mention that the 
LAR after exercise is not IgE dependant in contrary to the LAR after allergen exposure. 
Neuropeptide release, mediator release from bronchial mucosa resident cells or even the reactive 
hyperaemia in the bronchial mucosa which follows the vascular constriction due to 
hyperventilation-induced heat loss can cause delayed bronchoconstriction and increased 
sensitivity of airway smooth muscle [9]. It is argued that the elevated level of mediators 
measured in the blood in the EAR and LAR after exercise challenge has no meaning at all [38]. 
Also, it is well known that inhalation of warm humid air during exercise challenge causes a 
refractory period for a next exercise challenge, which is a rather stimulus-specific phenomenon 
[24, 39]. 
The cellular events taking place during the LAR after exercise challenge are still 
unknown. [33] 
1- 4. Therapy of the EAR and LAR after allergen and exercise challenge 
The EAR after allergen challenge can be prevented by the use of bronchospamolytic 
agents - especially inhaled ß-sympathicomimetics are effective. Also disodium cromoglycate is 
potent in inhibiting an EAR after allergen challenge[40]. Nedocromil sodium (Tilade^) has been 
shown to inhibit immediate bronchoconstriction provoked by challenge with allergen.[41] 
Inhibition of bronchoconstriction exhibited dose dependency up to 4 mg, with nedocromil 
sodium being up to four times more potent than sodiumcromoglycate. 
The LAR after allergen challenge can be prevented by the use of disodium cromoglycate 
and oral glucocorticosteroids. Theophylline preparations and ß-sympathicomimetics are less 
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effective. Nedocromil sodium prevents both phases of the dual asthmatic response to bronchial 
antigen challenge when it is inhaled before provocation. [42] 
The EAR after exercise challenge can be prevented by the use of bronchospamolytic 
agents - especially inhaled ß-sympathicomimetics are effective. Theophylline preparations have 
also been shown to be (partly) protective. [43] Also disodium cromoglycate is potent in 
inhibiting an EAR after exercise challenge[40]. Nedocromil sodium (TiladeR) admitted one 
hour before provocation has been shown to inhibit immediate bronchoconstriction provoked by 
challenge with exercise.[44] One to four weeks of therapy with inhaled corticosteroids 
decreases the severity of the EAR after exercise challenge. [45, 46] Oral steroids are also 
capable of doing so. [47] 
Besides glucocorticosteroids, other pharmaceuticals can be used in prevention or therapy 
of the LAR after exercise challenge. Cromoglycates can prevent the LAR after exercise 
challenge [3,10]. Nedocromil sodium might be more effective than disodium cromoglycate in 
this respect [40, 41, 48, 49, 50]. Anticholinergics might be effective in a subgroup of patients 
with a LAR after exercise challenge [13, 51]. Theophylline preparations and ß-
sympathicomimetics are less effective. 
1-5. Clinical practise 
It is of very great importance to clinicians to recognize a late fall after an exercise 
challenge. Patients can visit their physician with pulmonary discomfort which could be related 
to performed exercise 3-13 hours before the complaints started. A number of nocturnal dyspnoe 
complaints can also be a late reaction to exercise. The recognition of a late fall is very easily 
done with a mini-Wright peak-flow meter. 
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2. Study population and aims of the study 
In this thesis the existence and prevalence of a LAR after exercise challenge were 
investigated in a group of patienu hospitalized in the Dutch Asthma Center Davos, Switzerland. 
In general, this population consists of patients with severe bronchial asthma and chronic 
obstructive pulmonary disease. All patients used optimal medical treatment for their airway 
obstruction such as inhaled ß-mimetic agents, inhaled anticholinergic agents, inhaled 
corticosteroids and nedocromil sodium or disodium cromoglycate. Furthermore, they needed 
oral bronchodilators such as theophylline preparations, oral ß-mimetic agents, anti-histaminic 
agents in case of allergy and in a high percentage of patients oral corticosteroids. A standardized 
exercise challenge was carried out in all patients according to Eggleston to detect exercise-
induced asthma. ',2 [52,53] 
In chapter 2 the prevalence of the EAR and LAR after exercise challenge was studied in 
patients with reversible airflow limitation. The importance of a control day in the assessment of 
a LAR after exercise challenge was investigated in relation to other parameters such as the pre-
exercise PEFR value. 
The normal variability of the PEFR during the course of the day was assessed in chapter 
3 and this variability is used to detect late asthmatic responses after exercise challenge. The 
distinction between real and pseudo late asthmatic responses after exercise challenge was made 
on stronger criteria to identify late responses. The question was analyzed if it was possible to 
get more information and a better definition of the LAR after exercise challenge by looking at 
figures from PEFR recordings instead of looking at percentages peak flow fall. 
In chapter 4 the reproducibility of a LAR after exercise challenge was investigated in 
another group. It was studied if LARs after exercise challenges were still developing when 
more strict criteria were taken into account such as a PEFR fall on 3 or more time points 3-13 
'The maximal predicted heart rate was calculated as' R ma*=209-O.74(age in years) 
2Thepredicted maximal workload was calculated for man :f0.9CfiO-0.55ape in veaniïl-C'i.H-t-weif hl+lSll 
10.5 
The predicted maximal workload was calculated for woman :Г0.9(48-0.37ауе in vearsil-(S.8+weight+15n 
10.5 
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hours after exercise challenge compared to corresponding clock time on a control day. Using 
these criteria it was studied if the same LAR again was present after a second repeatable exercise 
challenge. How reproducible was the time at which the LAR occurs? 
In chapter 5 a study was performed to start to elucidate the pathophysiological 
mechanism behind the LAR after exercise challenge. In patients with a reproducible positive 
LAR after exercise challenge a bronchial provocation test was done on different time points and 
blood was collected for analysis of inflammatory cells such as neutrophils, eosinophils and 
basophils. Furthermore, serum histamine and serum-eosinophilic canonie protein were analyzed 
in order to detect changes in these parameters in comparison with a group of patients with a 
reproducible negative LAR after exercise challenge. 
In chapter 6 the protective effect of nedocromil sodium was investigated on the EAR and 
LAR after exercise challenge, in a double blind placebo controlled cross-over design study. 
In chapter 7 a summary of the investigations in this thesis is given. 
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CHAPTER 2 
IMMEDIATE AND LATE ASTHMATIC RESPONSES INDUCED BY 
EXERCISE IN PATIENTS WITH REVERSIBLE AIRFLOW LIMITATION 
B.Speelberg 
N.J. van den Berg 
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Abstract. 
The existence and prevalence of late asthmatic responses to exercise in patients is uncertain. We 
investigated whether the late falls of peak expiratory flow rate (PEFR) after exercise challenge 
were still significant after comparison with the corresponding clocktime PEFR on a control day. 
We examined 86 patients with reversible airflow limitation, 79 with asthma and 7 with chronic 
obstructive pulmonary disease (COPD), all under regular treatment with bronchodilators and/or 
anti-inflammatory agents. Patients were randomized for a control day and an exercise day and 
their PEFR was recorded hourly. On the exercise day, each patient underwent an 8 minute 
bicycle ride at 90% of predicted maximal heart-rate. An early and a late asthmatic response to 
exercise were considered to occur when PEFR decreased by 10% or more on the exercise day 
compared to the corresponding clocktime PEFR on the control day. Thirtythree patients (38%) 
had a 10% or greater fall of PEFR at 4 to 13 hours after exercise when PEFR was compared 
with the coiresponding clocktime on a control day. Seven (8%) had an isolated late asthmatic 
response, and 26 (30%) had a dual asthmatic response. We conclude that true late asthmatic 
responses develop after exercise in a significant number of patients with well controlled 
reversible airflow limitation. 
Introduction. 
Exercise-induced asthma (E.I.A.) was first described in the 17th century by sir John Floyer [1]. 
At that time this phenomenon was regarded as a distinct clinical entity. Views began to change 
in 1962, when Jones et al. [2] had established for the first time that exercised-induced asthma 
could be a normal symptom of asthma. Now, exercise is considered as a common and potent 
trigger of bronchoconstriction in asthmatic patients [3]. According to Anderson [3], exercise-
induced asthma is proved by a 10% or greater fall of peak expiratory flow rate (PEFR) or 
forced expiratory volume in one second (FEVi) after exercise when compared to pre-exercise 
values. Patients with exercise-induced asthma may develop an early and/or a late asthmatic 
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response [4,5]. The early fall in PEFR or in FEVi develops within ten minutes after exercise, 
reaches a maximum after 20-30 minutes and normally disappears within 1-3 hours. The late 
response can occur after recovery from the early response and starts 4-12 hours after the 
exercise, decreases in severity 12 hours after challenge and has usually disappeared within 24 
hours after challenge. 
The prevalence of the late asthmatic responses to exercise is uncertain [6,7]. Rubinstein 
et al. [8] observed the same delayed asthmatic responses in most of their subjects during an 
exercise day and during a control day on which the FEVi was measured serially but no 
exercised was performed, demonstrating the lack of specificity of late responses to exercise; 
however, one of the patients examined had a true late asthmatic response, as shown by a 
delayed decrease of FEVi on the exercise but not on the control day [8]. Unfortunately, in most 
previous studies, FEVi after exercise was compared with FEVi before exercise [5,7, 9, 10] 
raising the suspicion that observed late asthmatic responses may represent a decrease of 
pulmonary function related to withdrawal form therapy [8]. 
In the present study, we examined the bronchoconstrictor response to exercise in a group op 
patients with reversible airflow limitation, and we calculated the number of late asthmatic 
responses obtained by comparing the percent fall of PEFR after exercise either with the 
corresponding clock time PEFR on a control day, or with PEFR before exercise on the exercise 
day. 
Patients and methods. 
We examined 115 patients hospitalized in the Dutch Asthma Centre Davos, Switzerland, and 
included in the study 86 patients with a PEFR greater than 65% of the predicted value [11]. 
Seventy-nine suffered from asthma, 7 had COPD (table 2-1). All patients with bronchial asthma 
as defined by the American Thoracic Society, had a documented bronchial hyperresponsiveness 
to histamine below 8 mg'ml·1 as measured according to Cockcroft et al. [12, 13]. Asthmatic 
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patients showed an FEV ι reversibility greater than 20% of predicted value after 4 puffs of 
salbutamol. Also the patients with COPD had a documented bronchial hyperresponsiveness to 
histamine below 8 mg«ml_1. In these cases, FEVi reversibility was less than 20% of predicted 
value after 4 puffs of salbutamol, and the PEFR was greater than 65% of predicted value. 
Throughout the study period all patients had to submit to concomitant medication rules: 
the patients had to stop inhaling bronchodilators 8 hours before the exercise challenge, and 
during the control day; sodium cromoglycate had to be stopped 24 hours before the test and 
during the control day; any type of oral bronchodilator had to be stopped at least 48 hours 
before the start of the exercise challenge and during the control day. The dose of oral and 
inhaled steroids was kept constant. All patients on steroids were using this treatment for at least 
3 months. Patients did not stop smoking during the study. 
The control- and exercise days were chosen at random. They were separated by a 
minimum of 72 hours and a maximum of 6 days in order to minimize the changes in the clinical 
situation of the patient. Consent was obtained from each of the adult patients and from the 
parents of the underage children. The protocol was approved by the Ethical Committee of the 
clinic. 
The degree of of airway hyperresponsiveness was measured as the concentration of 
inhaled histamine which resulted in a 20% decrease of FEVi, and expressed as PC20FEV1 
(mg.ml-·) [12]. 
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Table 2-1: Patient charactenstics. FEVi: forced expiratory volume in one second; FVC: 
forced vital capacity; COPD: chronic obstructive pulmonary disease. PC20: concentration of 
histamine that gives a 20% decrease in FEVi. 
Characteristics total qroup with reversible airway obstruction 1 
Age (yrs) 
Sex 
Children/Adults 
Clinical diagnosis 
Atopic status 
Smokers 
Steroids none/oral/mhaled/both 
Histamine PC 20 (mg/ml) 
Baseline FEVI (L, % predicted) 
FVC (L, % predicted) 
27 2 ± 14 1 
46 Male. 40 Female 
32/54 
79 Asthma, 7 COPD 
71 Atopic, 15 Non-atopic 
10 Smokers, 76 Non-smokers 
9 /7 /41 /29 
1.1 ± 1 6 
2 85 ± 0 83: 86 7 ± 23.9 
4 05 ± 1 00, 101 9 ± 18 6 
Characteristics children with reversible airway obstruction 
Age (yrs) 
Sex 
Atopic status 
Smokers 
Steroids none/oral/mhaled/both 
Clinical diagnosis 
Histamine PC 20 (mg/ml) 
Baseline FEV1 (L, % predicted) 
FVC (L, % predicted) 
152 ± 1 4 
23 Male, 9 Female 
31 Atopic, 1 Non-atopic 
1 Smoker, 31 Non-smokers 
3 /3 /24 /2 
32 Asthma, 0 COPD 
10 1 1 2 
2 67 ± 0 75, 86 8 ± 23 5 
3 77 ± 0 89, 101 8 ± 17 2 
Characteristics adults with reversible airway obstruction I 
Age (yrs) 
Sex 
Clinical diagnosis 
Atopic status 
Smokers 
Steroids none/oral/mhaled/both 
Histamine PC 20 (mg/ml) 
Baseline FEV1 (L. % predicted) 
FVC (L, % predicted) 
34 2 ± 13.5 
23 Male, 31 Female 
47 Asthma, 7 COPD 
40 Atopic 14 Non-atopic 
9 Smokers, 45 Non-smokers 
6 /4 /17 /27 
1.1 ± 1 8 
2 95 ± 0 86; 86 6 ± 24 4 
4 21 ± 1 03, 101 2 ± 19 5 
Exercise challenges were performed on a bicycle ergometer (Erich Jager, Wurzburg, 
Germany). The workload in Watts was 80% of the predicted maximum workload. The 
predicted maximum workload was calculated according to Wasserman [14]. Exercise had been 
performed for 8 minutes during which a heart rate of 90% of the predicted maximum was 
reached [15, 16]. During the exercise challenge the heart rate was measured by a Siemens 
Sirecust 341 monitor (Siemens, Germany). The relative humidity of the ambient air was 20-
40%, the room temperature was 20-23° Celsius, both on the control and the exercise day and 
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both were measured with the Hygrotest 6200 (Quarz AG, Zürich, Switzerland). The humidity 
and room temperature were allowed to oscillate about 10% during control- and exercise day for 
each patient 
PEFR was measured with the mini-Wright peakflow meter. The best of three 
measurements was recorded. PEFR was recorded on the control day at t=0 and during the first 
13 h after t=0 at hourly intervals; on the exercise day PEFR was recorded at t=0 (pre-exercise 
PEFR) and 1, 3, 5, 7, 10, 15 and 30 minutes, and then hourly during the next 13 h after the 
end of the exercise challenge. 
The existence of exercise-induced asthma was inferred from the calculation of the 
formula in table 2-2. The early fall after exercise was calculated with the pre-exercise value as a 
reference. 
The late fall in PEFR after exercise was calculated using four methods. 
1. The lowest PEFR 4-13 h after exercise in relation with the pre-exercise PEFR. 
2. The lowest PEFR 4-13 h after exercise in relation with the PEFR at the same time on the 
control day. 
3. Because of the broad range of PEFR values in different patients (age, FEVi), we corrected 
for the differences in baseline PEFRs among subjects by including the predicted PEFR values 
in the formula. 
4. We calculated the mean PEFR on the control day for each patient and related it to the lowest 
PEFR 4-13 hours after exercise. 
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Table 2-2:Formu]ae used to calculate the early and the late reaction after an exercise challenge. 
Fall early, 
for ulae used to calculate the early and the late reaction after an exercise chai [ PEFR ¡mmediatelyj fLowest PEFR ~| before exercise J -
 after exercise 1-30 min. 
f, ib - - : ==—i= χ 100% 
PEFR immediately before exercise 
Fall pEFR immediateiyj_ [lowest PEFR ~| 
late [before exercise J "[after exercise 4-13 hrsj 
% pre-exercise - x 100% 
PEFR immediately before exercise 
Fall | PEFR on corresponding ~\ _ [lowest PEFR 
late 
% of control day < 
[ "~| "~| clocktime on control day after exercise 4-13 hrs.l 
— - Ι χ 100% 
PEFR on corresponding clocktime 
[PEFR immediately] _ [lowest PEFR Ί 
[before exercise J ~ [after exercise 4-13 hrsj 
Fall 
late 
% predicted . — — !z —
 χ
 ^пло^ 
PEFR predicted 
Elean PEFR on control day] - [Lowest PEFR ~| 
_J [after exercise 4-13 hrsj 
Fall 
late _ 
% mean control - — — — — χ 100% 
Mean PEFR on control day 
A fall in PEFR greater than 10% was considered positive for the existence of the early 
and/or late bronchoconstrictive response after exercise [3]. We separately registered PEFR falls 
of 10-20% and falls greater than 20%, because we wondered whether PEFR fall of greater than 
10% was sufficient enough to establish a late reaction after exercise. 
Results. 
The results of this study are presented in table 2-3 and in figures 2-1 and 2-2. The 
baseline PEFR values on the control and exercise day were not comparable, the baseline PEFR 
on the exercise day being higher than PEFR on the control day (control day baseline value 333 
± 88 , exercise baseline value 367 ± 65; P<0,01). 
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Figure 2-l:The percentage of paüents with a PEFR fall after exercise. The patients are registered 
separately, according to whether the pre-exercise PEFR, or the corresponding clocktime on a 
control day was taken as a reference. Above the dotted line all late respondents with a PEFR fall 
greater than 20% are registered. 
LAR>20% 
EAR>20%and LAR>20% 
EAR 10-20% and LAR>20% 
EAR>20% 
EAR>20% and LAR 10-20% 
LAR 10-20% 
EAR10-20% and LAR10-20 % 
EAR 10-20% 
No reaction 
LR>20% 
% Patients, control day as a reference 
% Patients, pre-exercise PEFR as a 
I reference. 
Table 2-3:Number of patients with an early and a late reaction after exercise In one column 
PEFR fall is compared to pre-exercise PEFR In the other column PEFR fall is compared to the 
corresponding clock time on a control day. Patients are separately registered as children (< 17 
years) and adults (> 17 years).EIA = exercise induced asthma.EAR = early asthmatic 
response.LAR = late asthmatic response. 
Delirad subgroups 
EAR < 10%, LAR < 1 0 % 
EAR 10-20 %, LAR < 10 % 
EAR > 20%, LAR < 1 0 % 
EAR < 10 %, LAR 10-20 % 
EAR 10-20 %, LAR 10-20 % 
EAR > 20 %, LAR 10-20 % 
EAR < 10%, LAR > 2 0 % 
EAR 10-20 %, LAR > 20 % 
EAR > 20 %, LAR > 20 % 
Total 
Maximal tall in PEFR compared to 
pre-exercise level on same day (exercise) 
Children 
10 
9 
6 
1 
1 
4 
0 
0 
1 
32 
Adults 
14 
6 
6 
4 
1 
2 
4 
3 
14 
54 
All 
24 
15 
12 
5 
2 
6 
4 
3 
15 
86 
Maximal lall in PEFR compared lo 
same time level on control day (no exercise) 
Children 
9 
9 
5 
1 
1 
3 
1 
0 
3 
32 
Adults 
18 
5 
7 
4 
4 
4 
1 
1 
10 
54 
All 
27 
14 
12 
5 
5 
7 
2 
1 
13 
86 
With the pre-exercise PEFR as a reference, 24 patients showed neither an early nor a late 
response after exercise. A late asthmatic response to exercise with a fall in PEFR of greater than 
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20% compared to pre-exercise value occurred in 22 (26%) of the 86 patients who completed the 
exercise challenge. Five patients had an isolated late response with a peak-flow fall of 10-20%. 
Four patients had an isolated late response with a peak-flow fall greater than 20%. The percent 
changes of PEFR from baseline on the control and exercise days of 2 patients who developed a 
late asthmatic response after exercise are illustrated in figure 2-3. In these patients, the 
maximum decrease of PEFR from pre-exercise PEFR was 33±21% and 36±14% during the 
early and late asthmatic response, respectively. 
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Figure 2-2 Number of patients with EIA and late falls in PEFR after an exercise challenge. The 
fall in PEFR is expressed only for the LAR in 10-20% and >20%.For the calculation of the 
number of patients with an EAR and LAR see table 2-2. 
Response in relation to : 
LAR 
10-20% 
Corresponding 
clocktime 
10-20% 
Pre-exercise/ 
Predicted 
Pre-exercise/ 
mean control day 
37 
LAR A LAR 
10-20% / \ >20% 
No EIA 
LAR 
10-20% 
18 19 
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Figure 2-3 PEFR data for 2 patients with a LAR to exercise. The upper curve demonstrates a 
patient with a late response in relation to the pre-exercise value. PEFR immediately before 
exercise is 260. The late fall after exercise calculated according to table 2-2 is 23%. The lower 
curve demonstrates a patient with a late response in relation to corresponding clocktime on a 
control day. The calculate late fall after exercise according to table 2-2 is 16%. 
PEFR 
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3 0 0 
2 5 0 -г ^ o -
2 0 0 •• 
1 5 0 •• 
100 •-
5 0 •• 
\ _.© or 
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9 1 0 
l/min 
450 
4 0 0 ^ 
3 5 0 -
3 0 0 -
2 5 0 . . 
200-. 
150 -· 
100-· 
50- · 
0 
Lr^s^·- • -
.У 
Э 1 1 
5 * 
1 2 13 
Time (hr) 
- · - Control day 
-o- Exercise day 
1 
H 1 1 1 1 1 1 1 »- H 1 
11 13 
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If PEFR 4-13 h after exercise was compared with the same time on the control day, 27 
patients showed no response after exercise. A late asthmatic response to exercise with a fall in 
PEFR greater than 20% compared to control day occurred in 16 (19%) of the 86 patients who 
completed the exercise challenge. Five showed an isolated late response with a PEFR fall of 10-
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20%. Two patients had an isolated late response with a PEFR fall greater than 20%. Thirteen 
patients had an early response as well as a late response with a peak flow fall both greater than 
20%. 
Children developed an isolated early asthmatic response to exercise more frequently than 
adults, both if PEFR after exercise was compared with PEFR before exercise (children 46.9% 
adults 22.2%) and with the corresponding clocktime PEFR (children 43.7% adults 22.3%). By 
contrast adults developed a late asthmatic response to exercise more frequently than children. 
Twenty-one adults had a fall of PEFR greater than 20% after exercise when PEFR fall was 
compared to pre-exercise value and 12 when PEFR fall was compared with the corresponding 
clocktime PEFR on a control day. When the lowest PEFR value 4-13 h after exercise was 
compared with the corresponding clocktime on the control day, 33 patients (38%) had a fall of 
PEFR greater than 10% and 16 (19%) greater than 20% on the exercise day. 
Despite the use of oral steroids, 3 patients developed a late asthmatic response after 
exercise when PEFR was compared with the pre-exercise value. Ten patients had a late 
asthmatic response of greater than 20% using both oral and inhaled bronchodilators. The mean 
starting time of PEFR greater than 20% was at 6.0 ±2.1 hours after exercise when PEFR was 
compared to the control day and 9.0±2.4 hours, when PEFR fall was compared with the 
corresponding clocktime PEFR on the control day. 
All seven patients with COPD developed a late asthmatic response after exercise if the 
fall of the PEFR was calculated on the pre-exercise PEFR, and 6 of them if the fall of PEFR 
was calculated on the coiresponding clocktime PEFR on a control day. 
Discussion. 
In our study we compared the post-exercise decrease in PEFR to the corresponding 
clocktime PEFR on a control day. We found a considerable number of late responses. We 
demonstrated that the late response can occur without an early response. The late response after 
exercise can occur as an isolated or as a dual response. A late response was present despite the 
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use of oral and inhaled steroids. These drugs have been shown to play a protective role in the 
late asthmatic response after allergen provocation [17]. The mechanisms of exercise-induced 
late responses seem to be quite different from those responsible for the late responses to 
allergens, because the late response is much less reproducible and shorter lasting [10]. 
The prevalence of early, exercise induced asthma (EIA) is as stated in literature [18]. 
Children are relatively more affected with EIA than adults. For the late response, the contrary is 
shown. Asthmatic patients older than 17 years are relatively more affected by the late response 
after exercise than patients younger than 17. 
Our results are different from those of Rubinstein et al., who also used a control day in 
their experiments. Rubinstein et al. demonstrated the lack of specificity of late responses to 
exercise in most subjects, but found one patient having a true late fall in FEVi after exercise 
challenge. The controversy in the literature about the late asthmatic response to exercise is 
whether or not late responses to exercise do occur and if so, what is their frequency. The 
difficulty of analyzing this problem is the following: to which value should a fall in PEFR of for 
instance >20%, 4-13 hours after exercise be related? Is this the pre-exercise value, or the value 
at corresponding clocktime on a control day, or the pre-exercise/predicted PEFR, or the pre-
exercise/mean value on the control day, or perhaps another value? We do not agree with 
Rubinstein et al. that the late asthmatic response to exercise is an epiphenomena (figure 2-2) 
because we demonstrated 16 patients having a LAR >20% to exercise when PEFR fall was 
compared to corresponding clocktime on a control day. We do agree with Rubinstein et al. that 
PEFR fall after an exercise challenge should be related to corresponding clocktime on a control 
day, also without medication. In this way the diurnal variation of airway calibre can be taken 
into account. Few investigators have used a control day in the examination of the existence of a 
late fall in PEFR or'FEVi after an exercise challenge [8-10,19]. 
One should consider the effect of stopping drugs on PEFR or FEVi. For this reason, 
the control day is particularly important. In studies without a control day the diurnal post-
exercise rhythm is not compared with the diurnal rhythm of a day without exercise. We used in 
our study the PEFR. Other investigators took the FEVi [9]. We consider the mini-Wright peak 
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flow meter a good instrument for recording the PEFR after an exercise challenge. We reported 
our results according to Anderson's definition of EIA [15, 16]. This definition describes a fall 
in post-exercise PEFR greater than 10%. There is no agreement in the medical literature whether 
the percentage of a PEFR fall after an exercise challenge should be 10 or 20%. It depends on 
the spontaneous variability of the parameters for the population studied. If a change in PEFR > 
10% is considered, spontaneous variability has to be < 10%. We considered that a PEFR fall 
greater than 20% may cause a late asthmatic response. 
In contrast to our study Bierman [20] stated that it is important to perform a control day 
before the exercise day instead of after it, because the preceding late response may have 
changed the subjects' airway responsiveness and subsequent diurnal variations in PEFR. 
In our study we came across a considerable number of patients using oral and inhaled 
steroids who had a late fall after an exercise challenge. Why these efficient drugs given in 
adequate pharmacological amounts did not prevent the late fall, is not quite clear to us. It is 
possible that without steroids, the patients would have had a much more severe late response. 
There may be two reasons for the occurrence of late responses to exercise in corticosteroid 
treated patients. First, the dose of corticosteroids may not be sufficient to control symptoms 
and/or prevent induced inflammatory responses associated with the late responses. Secondly, 
the late responses to exercise may not be associated with inflammatory responses of the 
airways. Exercise can induce increased airway responsiveness, with or without late responses 
as allergen exposure does, but this does not imply that inflammation is involved in the genesis 
of these phenomena as seen with allergen [10,21]. Neuropeptide release, mediator release from 
bronchial mucosa resident cells, or even the reactive hyperaemia in the bronchial mucosa which 
follows the vascular constriction due to hyperventilation-induced heat loss can cause delayed 
bronchoconstriction and increased sensitivity of airway smooth muscle [22-24]. Boulet et al. 
[19] showed an unchanged bronchial reactivity to histamine 24 hours after the exercise. 
Lee et al. [25] found no fall in FEVi after acetylcholine inhalation, in six persons with 
documented exercise-induced late response, indicating that an exercise-induced late-phase 
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response is more than the non-specific sequel of previous bronchoconstriction or a resjxmse to 
drug withdrawal. 
It is of very great importance to clinicians to recognize a late fall after an exercise 
challenge. Patients can visit their physician with pulmonary discomfort which could be related 
to performed exercise 4-13 hours before the complaints started [26]. A number of nocturnal 
dyspnea complaints can also be a late response to exercise. The recognition of a late fall is very 
easily done with a mini-Wright peak flow meter. The early response can be prevented by 
inhaling ß-sympathicomimetics, or disodium cromoglycate [27, 28]. 
We should only speak of a late response after an exercise challenge, when the diurnal 
post-exercise rhythm has been compared with a diumal rhythm of a day without exercise. This 
is demonstrated in figure 2-3, in which the upper curve shows a PEFR fall to exercise of 23% 
and the lower curve of 16%. Although the percentage fall in PEFR after exercise is higher in the 
upper curve it is nog a late response to exercise because the variation in the PEFR is due to 
circadian variation in airway calibre. One can never say that a patient has a late asthmatic 
response to exercise when a PEFR fall is related only to рге-exercise value. To draw a graph, 
instead of looking at figures, may be more illustrating for demonstrating a late asthmatic 
response to exercise. 
Not all patients who had a late PEFR fall as compared with рге-exercise value, had a late 
PEFR fall when peak-flow decrease was compared with the corresponding clocktime on a 
control day. We think a PEFR fall greater than 20% can sufficiently demonstrate a late response 
after exercise. We demonstrated that the late bronchoconstrictive response after exercise had a 
prevalence of 38% when PEFR fall greater than 10% was compared with the corresponding 
clocktime on a control day. The percentage was 19% when PEFR fall of greater than 20% was 
compared with corresponding clocktime on a control day. 
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Responses asthmatiques immédiates et tardives, induites par l'effort, chez les patients atteints de 
limitation réversible du débit aérien. B. Speelberg, N.J. van den Berg, C.H.A. Oosthoek, 
N.P.L.G. Verhoeff, W.T.J, van den Brink. 
RÉSUMÉ: L'existence et la prévalence des responses asthmatiques tardives à l'effort chez les 
patients sont incertaines. Nous avons investigué si les chutes tardives du débit expiratoire de 
pointe après une provocation d'effort étaient encore significantives après comparaison avec le 
débit expiratoire lors d'un jour de contrôle à la même heure. Nous avons examiné 86 patients 
souffrant d'une diminution réversible des débits gazeux, 79 atteints d'asthme, et 7 de BPCO, 
tous sous traitement régulier aux bronchodilatateurs et aux agents anti-inflammatoires. Les 
patients ont été répartis de façon randomisée en un jour de contrôle et un jour d'effort, avec 
enregistrement horaire du débit expiratoire de pointe. Pendent le jour d'effort, chaque patient a 
subi une épreuve à la bicyclette pendent 8 minutes à 90% du pouls cardiaque prédit. Une 
response asthmatique précoce et tardive à l'effort a été considérée comme présente si le débit de 
pointe diminuait de 10% ou davantage le jour de l'effort, par comparaison à la même heure le 
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jour de contrôle. Trente-trois patients (38%) ont montré une chute du VEMS de 10% ou 
davantage entre 4 et 13 heures après l'effort, lorsque le débit de pointe était comparé avec le 
débit correspondant à la même heure le jour contrôle. Sept (8%) n'ont manifesté qu'une 
response tardive isolée, et 26 (30%) ont eu une réaction asthmatique double. Nous concluons 
que des réactions asthmatiques tardives authentiques se développent après l'effort chez un 
nombre significantif de patients atteints d'une limitation réversible mais bien contrôlée des 
débits aériens. 
Eur Respir J., 1989, 2, 402-408. 
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Abstract 
The late asthmatic reaction after exercise challenge remains a controversial issue. In this 
study 21 patients recorded peak expiratory flow rate (PEFR) on two control days without 
performing exercise. There was no difference between both control days when PEFR at 1 hour 
was compared to baseline PEFR and when PEFR at 4-13 hours was compared to baseline 
PEFR. After analyzing variation coefficients of baseline PEFR on a control- and exercise day 
PEFR was not allowed to differ more than 15.3 % in the same patient, when comparing 
exercise- and control day for the late fall in PEFR in the study. In 17 out of 81 patients a late 
asthmatic reaction after exercise challenge was present, when PEFR fall was >20% compared to 
baseline PEFR value. In 8 out of the 17 patients a real late asthmatic reaction to exercise 
challenge was present with a PEFR fall à20% on at least 3 successive time points and who had 
a PEFR fall £20% compared to corresponding clocktime on a control day. The late asthmatic 
reaction to exercise challenge is characterized not as an non-specific epiphenomenon, but as a 
fall in PEFR of £ 20% both compared to baseline PEFR value and to corresponding clocktime 
on a control day on at least 3 successive time points. Graphic illustration of airway responses 
following exercises may facilitate the detection of a late asthmatic responses. 
Abbreviations used : 
PEFR: Peak Expiratory Flow Rate 
EIA: Exercised Induced Asthma 
EAR: Early Asthmatic Response 
LAR: Late Asthmatic Response 
EC: Exercise Challenge 
Key words : Exercise - asthma - early asthmatic reaction -late asthmatic reaction -peak 
expiratory flow rate. 
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Introduction 
In 1980, Bierman et al. reported for the first time a late asthmatic response (LAR) after 
exercise challenge (EC).1 The LAR stans 3-12 hrs after EC and may last for several days.2·^ 
According to Anderson et al., a LAR is defined as a fall in peak expiratory flow rate (PEFR) or 
in forced expiratory volume in 1 second (FEV1) greater than 10 percent of baseline.^ The 
prevalence of a LAR after EC has been reported to vary between 2-60 peicent.5-9 Recently, the 
existence of a LAR after EC has been challenged.^·1^,! 1 These investigators looked at a LAR 
after EC as a nonspecific epiphenomenon, to be the result from medication withdrawal before 
EC, and cyclic changes in pulmonary function and airway hyperresponsiveness. It was stated in 
a recent review, that cumulative evidence indicates that a LAR after exercise may occur, but that 
the prevalence of it is uncertain. Furthermore, that decrements in airways calibre may occur 
simply as the result of withdrawal of medication.12 In a group of 86 patients with reversible 
airflow limitation, a LAR after EC, considered to occur when PEFR decreased by 20 percent or 
more on an exercise day compared to the corresponding clocktime PEFR value on a control 
day, was demonstrated to have a prevalence of 19 percent. In this study of Speelberg et al. it 
was suggested that there is no agreement in the medical literature whether the percentage of a 
PEFR fall after an EC should be 10 or 20 percent, depending on the spontaneous variability of 
PEFR in the population studied. It was also suggested that drawing graphs, instead of looking 
at figures, may be more illustrative for demonstrating a LAR after EC.^ 
In the present study we investigated the prevalence and pattern of the fall in PEFR after 
EC in patients with asthma studied by Speelberg et al. The effects of withdrawal of treatment 
and EC were separated by monitoring PEFR after medication withdrawal only and after 
medication withdrawal followed by EC. Spontaneous variability of PEFR in the population is 
determined and graphs are drawn of those patients demonstrating a late fall in PEFR after EC of 
more than 20 percent 
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Patients and methods 
The study consisted of two parts. In study 1, PEFR was measured on two separate 
study days after withdrawal of medication without exercise. This study was performed to 
determine spontaneous PEFR variability on two separate days in the population studied. In 
study 2, PEFR was measured after the same medication withdrawal regimen as in study 1 on a 
day without exercise (control day) and on a day on which a submaximal EC was performed 
(exercise day). This study was performed to determine the prevalence of a late fall in PEFR £ 
20 % after EC in the patients studied and to visualize this late fall in PEFR in graphs, both on 
control and on exercise day. 
In the study, an early asthmatic reaction (EAR) was defined as a fall in PEFR from 
baseline of at least 20 percent 1-60 min after EC. A LAR was defined as a fall in PEFR from 
baseline of at least 20 percent 4-13 hours after EC.9 A true LAR was defined as a fall in PEFR 
from baseline of at least 20 percent on 3 successive occasions 4-13 hours after EC on the 
exercise day, without a similar fall in PEFR from baseline at similar time points on the control 
day. A pseudo LAR was defined as a fall in PEFR from baseline of at least 20 percent 4-13 
hours after EC on the exercise day, accompanied by a similar fall in PEFR from baseline at 
similar time points on a control day. 
Study 1 
This study was done in 21 asthmatic patients who were treated in the Dutch Asthma 
Centre Davos and who fulfilled the following inclusion criteria: (a) age 12-65 years; (b) clinical 
diagnosis of bronchial asthma, according to the criteria of the American Thoracic Society №; (c) 
baseline PEFR (first measurement in the morning on each of both study days) ä 65 percent of 
predicted; (d) PC20 to histamine (the concentration of histamine which resulted in a 20 percent 
decline in FEVI of baseline was measured) й 8 mg/ml M. Patients characteristics are given in 
table 3-1. 
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Table 3-1. Characteristics of patients in study 1 
Number of patients 
Age (yrs, mean±SD) 
FVC (% predicted, mean±SD) 
FEVI (% predicted, meantSD) 
Histamine PC20 (mg/ml, mean±SD) 
Corticosteroids none/oral/inhaled/both (number of patients) 
21 
25.8 ±14.1 
98.9 ± 12.4 
81.0 ± 21.3 
1.5 ± 2.6 
1 /5 /1 1/4 
Characteristics of patients in study 2 
Number of patients 
Age (yrs, meantSD) 
FVC (% predicted, meantSD) 
FEVI (% predicted, mean±SD) 
Histamine PC20 (mg/ml, mean±SD) 
Corticosteroids none/oral/inhaled/both (number of patients) 
81 
25.5 ± 1 1 . 7 
103.0 ± 18.3 
89.0 ± 22.9 
1.0 ± 1.7 
9 / 7 / 4 5 / 2 6 
Oral bronchodilators were stopped 48 hours and disodium cromoglycate 24 hours 
before the study day and inhaled bronchodilators were stopped à 8 hours before. Oral and/or 
inhaled corticosteroids were continued. 
PEFR was measured with a mini-Wright peak flow meter (Airmed®) ten times in the 
first 30 minutes in the morning and hourly thereafter for 13 hours. The peak flow meters were 
cleaned after each measurement to prevent excessive humidity. The best of 3 consecutive PEFR 
values was recorded. 
Study 2 
One hundred and ten patients who were treated in the Dutch Asthma Centre Davos and 
fulfilled the same inclusion criteria as in study 1 were selected. PEFR was first measured on a 
control day as in study 1 with the exception that in the first 30 minutes in the morning PEFR 
was measured only once. In 81 patients the PEFR values on the control day and on the morning 
of the next day were not below 65 percent of predicted value. These patients were exercised. 
Their characteristics are shown in table 3-1. The patients started EC exactly at the same time as 
the first PEFR-measurement on the control day. Room temperature was 18-23 0C and relative 
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humidity of ambient air 20-40 percent. EC consisted of 8 min cycling on a bicycle ergometer 
(Erich Jäger, Würzburg, Germany). Workload was gradually increased until 80 percent of the 
predicted maximal heart rate was reached and continued for at least 4 min at this level." During 
EC, heart rate and ECG were monitored (Sirecust® 341, Siemens. Germany). The subjects 
wore a nose clip. 16 prior to EC, baseline PEER was measured twice with an interval of 5 min. 
After EC, PEER was measured at 1, 3, 5, 7, 10, 15, 30 min and 1 hour and hourly for 12 
hours as on the control day. 
The protocol was approved by the Ethical Committee of the Centre and all patients gave 
written mformed consent. 
Statistics 
Study 1 
The coefficient of variation of the PEER was calculated over the 13 hour measurement 
period on both study days in the 21 asthmatic patients. 1? In each patient the 10 PEER values in 
the first 30 minutes of both study days were compared by analysis of variance in patients to 
determine day to day variability in baseline value. From this the within-subject difference in 
baseline value on the control and exercise days allowed in study 2 was defined. Variability and 
reproducibility of the PEER on the entire study days in the 21 patients were analyzed by 
repeated measurements analysis of variance.'° 
Study 2 
The coefficient of variation of the PEER was calculated over the 13 hour measurement 
period on the control day in the 81 asthmatic patients who cycled and compared to the PEER 
variability in the groups of study 1 and 2. In order to assess whether a late fall in PEER ä 20 
percent was more frequent on the exercise day than on the control day, Mc Nemar's test for 
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paired dichotomic observations was used. 18 The magnitude of the early and the late fall in 
PEFR on the exercise day was compared by a two-tailed paired t-test. In patients in whom no 
PEFR measurements were missing, the difference between the values of the early and the late 
fall in PEFR on the exercise and the control day was analyzed by repeated measurements 
analysis of variance. ^  An early fall was defined here as a >20% fall from baseline PEFR 
within 1 hour after EC. 
Results 
Study 1 
The mean coefficient of variation in 21 patients of the PEFR on both control days was 
4.6 ± 2.9 percent. It was slightly larger on the first day (5.1 ± 3.3 percent) than on the second 
(4.0 ±2.6 percent). When these coefficients of variation of the PEFR on the first and second 
study day were compared by a two-tailed paired t-test, the difference was not statistically 
significant (P> 0.15). 
Baseline PEFR variability in the first 30 min of both control days was split up in 3 
components, due to different sources of variability. The first coefficient of variation, due to 
within patient variation of PEFR on one control day, was 3.9 percent The second coefficient of 
variation, representing the within patient variation between PEFR on both control days, was 3.7 
percent. The third coefficient of variation, describing the variation in mean PEFR levels 
between patients, was also 3.7 percent. The total within patient coefficient of variation of 
baseline PEFR values in the first 30 min of both study days was 5.4 percent. Assuming a 
Gaussian distribution and using 95 percent confidence intervals, we did not allow baseline 
PEFR on exercise and control day to differ more than 15.3 percent in the same patient when 
comparing exercise and control day fra- the late fall in PEFR in study 2. 
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In 9 out of the 21 patients who completely filled in their PEFR values repeated 
measurements analysis of variance on hourly recorded PEFR values on both study days 
revealed no early effect when PEFR at 1 hour was compared to baseline PEFR (P = 0.83) and 
no late effect when PEFR at 4-13 hours was compared to baseline PEFR (P = 0.32). There was 
no difference between both study days when PEFR at 1 hour was compared to baseline PEFR 
(P = 0.12) and when PEFR at 4-13 hours was compared to baseline PEFR (P = 0.88). 
Study 2 
The coefficient of variation of PEFR on the control day was 4.6 ±3.1 percent for the 
entire group of 81 patients who performed EC and 6.7 ± 2.5 percent for 17 patients with a 
LAR. 
On the basis of Mc Nemar's test (table 3-2), the hypothesis that a LAR after EC with a 
PEFR fall of £ 20 percent does not occur more often on the exercise day than on the control day 
had therefore to be rejected (P= 0.008). 
Table 3-2. Comparision of a late fall in PEFR from 
baseline on the control and exercise day, number of patients. 
Exercise day 
<20 % 
>20 % 
Control day | 
< 2 0 % 
64 
8 
>20 % 
0 
9 
Table 3-3. Characteristics of patients with a late fall in PEFR < 20 %, 
Number of patients 
Age (yrs, mean ± SD) 
FVC(% predicted, mean ± SD) 
FEVI (% predicted, mean ± SD) 
Histamine PC 20 (mg/ml, mean ± SD) 
Corticosteroids: none/oral/inhaled/both (number of patients) 
EAR i 20 % (number of patients) 
a real LAR and a 
PEFR fall < 20 % 
64 
23.8 ± 12.7 
104.2 ± 18.4 
90.3 ± 23.1 
1.1 ± 1.6 
6 / 4 / 3 5 / 1 9 
18 
pseudo LAR. 
Real LAR 
8 
29.9 ±11 .1 
107.4 ± 9.2 
87.3 ±19 .1 
1.3 ± 2.1 
2 / 1 / 3 / 2 
5 
Pseudo LAR 
9 
33.8 ± 10.9 
91.4 ± 20.7 
80.5 ± 24.0 
0.1 ± 0.1 
1 / 2 / 1 / 5 
6 
The magnitude of the early and the late drop in PEFR on the exercise day in the entire 
group of 81 patients who performed EC were significantly correlated, although the correlation 
47 
coefficient was small (r = 0.33; Ρ < 0.01). The early PEFR fall (18.9 percent) was significantly 
greater than the late PEFR fall (9.5 percent) (P = 0.0001). 
Repeated measurements analysis of variance revealed that the mean level of PEFR after 
EC was significantly lower on the exercise day than on the control day (P = 0.004). Also, the 
mean level of PEFR 4-13 hours after EC was significantly lower on the exercise day than on the 
control day (P = 0.01). 
For the 17 patients in whom PEFR fall was more than 20 percent 4-13 hours after EC, 
PEFR values on the control and the exercise day were compared at similar time points in graphs 
taking baseline value at the beginning of the day as 100 percent. There were 2 subgroups: (a) 
Eight patients in whom late PEFR decreased > 20 percent on the exercise day as compared to 
the control day on at least 3 successive points of measurement (figure 3-1). These were 
considered patients with a LAR, probably not caused by medication withdrawal (real LAR), (b) 
Nine patients in whom late PEFR on the exercise day and the control day showed no consistent 
difference (figure 3-2). In these subjects, a reason for the fall in PEFR was not clear (pseudo 
LAR). The characteristics of the patients with a fall in PEFR < 20 percent, a real LAR, and a 
pseudo LAR are compared in table 3-3. 
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Figure 3-l.PEFR on the exercise- and control day in 8 patients with a real LAR after EC. 
Baseline PEFR has been taken as 100% reference value. 
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Figure 3-2.PEFR on the exercise- and control day in 9 patients with a pseudo LAR after EC. 
Baseline PEFR has been taken as 100% reference value. 
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Discussion 
A rather high coefficient of variation for repeated PEFR measurements within 1 control 
day within 1 asthmatic patient was found in the first 30 min. This may be attributable to the 
rather high intra-instrumental variability of the Mini Wright Peakflow Meter, which sometimes 
differs about 15 % from a standardized flow value, especially in the low flow ranges. 1" As 
there was no statistically significant difference between the coefficients of variation of the PEFR 
in both control days, the coefficient of variation of the PEFR on control day in the patient group 
of study 1 was comparable to that in the patient group of study 2. 
By taking a limit of a fall in PEFR S 20 percent to define a LAR we were sure that this 
fall could not be explained on the basis of spontaneous variability in PEFR, since a 15.3 % 
variability is the upper limit of the 95 percent confidence interval. From the Mc Nemar test it can 
be concluded that a real LAR after exercise did occur in the group of the 81 asthmatic patients 
who performed an EC. This can also be concluded from the repeated measurements analysis of 
variance in the asthmatic patients who cycled and had completely recorded PEFR values. Also, 
the fact that the results were grossly the same when the PEFR value on the same time on the 
control day was taken instead of the baseline PEFR on the exercise day 9, is an indication that 
there was a real LAR after EC on the exercise day without an accompanying LAR on the control 
day. 
A real LAR occured in 8 patients, 10 % of the asthmatic population studied. The 
prevalence may have even been greater since not all patients could be taken off steroids therapy 
long enough. The pattern of the LAR in these 8 patients showed a variable pattern. PEFR 4-13 
hours after EC may fall to return quickly to baseline values, remain down for a long time or to 
decrease progressively (figure 3-1). 
These findings are in accordance with the literature, in which no significant differences 
were observed in clinical severity of asthma, age, sex, atopic status, and histamine PC20 
between patients with a single EAR and patients with both an EAR and LAR.2.5,20 
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An early fall ä 20 % occurred more than 2 times as often in patients with a LAR as 
compared to patients with a late fall in PEFR < 20 %. There was no difference, however, in 
EAR between the groups with a real and with a pseudo LAR. Two patients with a pseudo LAR 
and 1 patient with a real LAR did not have an EAR in our study. The more severe the early fall 
in PEFR, the greater the probability for a severe late fall in PEFR to occur. But a LAR to EC 
can occur without a preceding EAR. These results are in accordance with the literature in which 
it was proposed that a more severe EAR and LAR after EC are correlated 20-22) but that a LAR 
after EC can occur without a preceding EAR.5.8,9,11 
The early fall in PEFR after EC was found to be significantly greater than the late fall. 
This is in accordance with the findings in most studies in which a majority contends that the 
LAR is less prevalent and less severe than the EAR after EC 1.7,11 ^ d in contradiction with a 
minority that has found that the LAR is more severe.^ 
It could be possible that the LAR after EC results from an inflammatory reaction induced 
by the combination of airway water loss, airway cooling, hyperventilation and its metabolic 
consequences and a slow onset of adrenaline release during exercise. Airway inflammation is 
also an important etiological factor in LAR after allergen inhalation 23,24
 aii¿ ¡n LAR j n 
occupational asthma.25-27 ¡n
 o u r study, patients continued using steroids. These agents not 
only alter the late asthmatic response but also the normal variation of airway caliber.28,29 χ ^ 
observed variability in airway responses may be quite different when using glucocorticosteroids 
in patients with asthma. In this study is was for clinical reasons not possible to stop GC. The 
GC did not prevent a LAR to occur in 14 of the 81 asthmatic patients studied, although they 
used the steroids for at least 3 months before the start of the study. Therefore, either the actual 
prevalence of the LAR after EC may be greater than found in our study or the role of 
inflammation may play a less important role in the LAR after EC than in the other LARs 
discussed.^ Another possible cause could be the dose of steroids, which was perhaps not high 
enough. 
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Our results aie in contradiction with the hypothesis that the LAR after EC does not exist 
or is a non-specific epiphenomena. 
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Abstract. 
In this study the reproducibility of a late asthmatic reaction (LAR) after exercise 
challenge (EC) has been documented. Eighty three hospitalized asthmatic patients were 
challenged with exercise. The patients were examined according to a standardized protocol 
which comprised 8 minutes bicycling at 90% of predicted heart-rate. A LAR after EC was 
considered to take place when a fall in peak expiratory flow rate (PEFR) ^ 20% occurred on 3 or 
more time points on the exercise day when compared to corresponding clocktime on a control 
day. According to these criteria 11 patients (13.3%) experienced a LAR. Those patients were 
rechallenged 21-150 days after the first EC, without changing the therapy regimen of the 
patients, to study its reproducibility. Eight patients (73%) showed a reproducible LAR after EC 
based on the criteria for a positive LAR. Although the LAR after EC was reproducible, the time 
points at which the LAR took place after the second EC differed from those after the first EC. 
Our results indicate that the LAR after EC occurs in a considerable number of patients with 
bronchial asthma and is quite reproducible. 
Key words :exercise challenge - late asthmatic response - exercise induced asthma -
reproducibility. 
Introduction 
After exercise challenge (EC) asthmatic patients may show an early asthmatic response 
(EAR) and/or a late asthmatic response (LAR). The EAR is expressed as the fall in peak 
expiratory flow rate (PEFR) or in forced expiratory volume in 1 second (FEVI) and appears 
within 10 minutes after EC, reaches a maximum after 20-30 minutes, and disappears normally 
within 1-3 hours. A LAR after EC may occur after recovery from the EAR and starts usually 3-
13 hours after the EC, decreases in severity after 13 hours and usually disappears 
spontaneously within 24 hours. 1 
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Studies describing a LAR after EC have calculated the fall in PEFR compared to the pre-
exercise PEFR value. However, it has extensively been documented that it is more appropriate 
to relate a PEFR fall after EC to the corresponding clocktíme PEFR value on a control day 
instead of to the pre-excrcise PEFR value because of diurnal variation.2.3 Although in this way 
the LAR after EC can be much better described, we have attempted to further refine its 
definition in a previous study.4 Based on this study the LAR was defined as a PEFR fall ¿20% 
on three consecutive time points, implicating a period of S2 hours, 3-13 hours after EC in 
comparison with the corresponding clocktime PEFR value on a control day without exercise. 
Although the choice of a PEFR fall ä 20% on 3 consecutive time points still is arbitrarily this 
criteria allowed to discriminate between a LAR and a pseudo-LAR after EC.4 Furthermore in 
this study it was stated that graphical analysis of the PEFR changes after EC compared to 
corresponding clocktime values on a control day are necessary to properly describe the LAR. 
Moreover, during the LAR clinical symptoms have to be present. Therefore to our opinion this 
is a careful definition to describe a LAR after EC. Using this definition of a LAR after EC we 
have investigated whether the LAR after EC was reproducible. 
Patients and Methods 
Patients. 
All patients (n = 83) participating in the study were suffering from bronchial asthma as 
defìned by the American Thoracic Society 5 and the criteria mentioned below. Patients could not 
be diagnosed as having bronchial asthma and chronic obstructive pulmonary disease (COPD) 
simultaneously. 
Asthmatic patients had paroxysms of dyspnoea, wheezing, and cough. They had 
fluctuations in the severity of bronchial obstruction characterized by periods of a normal FEVI 
and by periods of an abnormal FEVI (below 70% of the predicted European Community for 
Coal and Steel value (ECCS)}, normalization in the severity of airflow obstruction (FEVI 
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greater than 70% of the predicted ECCS value) following the administration of bronchodilators 
or corticosteroids.^ All patients with bronchial asthma had a documented bronchial 
hyperresponsiveness, measured according to Hargreave et al. and expressed as the 
concentration of inhaled histamine which results in a 20% decrease of FEV1 (PC20 < 8 
mg/ml)7 
Throughout the study period all patients had to submit to concomitant medication rales. 
The patients had to stop inhaled bronchodilators 8 hours before the EC and during the control 
day. Sodium cromoglycate had to be stopped 24 hours before the exercise test and during the 
control day. Any type of oral bronchodilator had to be stopped at least 48 hours before the start 
of the EC and during the control day. The dose of oral and inhaled steroids was kept constant. 
All patients on steroids were using this treatment for at least 3 months. Patients did not stop 
smoking during the study. Smoking pattern remained the same during the study period. 
Informed consent was obtained from each of the patients. The characteristics of the patients 
with a LAR after EC are summarized in table 4-1. 
Table 4-1. Patient characteristics of the 11 patients showing a LAR after the first EC. * Atopy is 
defined as: three or more positive skin tests to common allergens. **Inh.:inhaled. 
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Exercise Challenge (EC) 
All ECs were performed on a bicycle ergometer (Erich Jäger, Würzburg, Germany). 
The maximal workload in Watts was 80% or less of the predicted maximum workload. The 
predicted maximum workload was calculated according to Eggleston.8 Exercise was performed 
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for 8 minutes during which a heart-rate of 90% of the predicted maximum was reached During 
the EC the heart-rate was measured by a Siemens Sirecust 341 monitor (Siemens, Germany). 
The relative humidity of the ambient air was 20-40%, the room temperature was 20-23° Celsius, 
both on the control and the exercise days and were both measured with the Hygrotest 6200 
(Quarz AG, Zürich, Switzerland). The humidity and room temperature were allowed to variate 
10% and 20C respectively during control- and exercise day for each patient. During the 8 min. 
bicycling the patients wore a noseclip. 
PEFR and FEVI measurements. 
PEFR was measured with the mini-Wright peakflow meter.9 All patients participating in 
the study were well trained in using the mini-Wright peakflow meter. Furthermore, the same 
peakflow meter was used at each occasion. The best of three measurements was recorded. 
Before and after each daily recording of peakflow rates, meters were checked and cleaned by 
the lung function technician. PEFR was recorded on the control day at t=0 (09.00 a.m.) and 
during the first 13 hrs after t=0 at hourly intervals; on the exercise day PEFR was recorded at 
t=0 hour (= pre-exercise PEFR) and 1, 3, 5, 7, 10, 15 and 30 minutes afterwards, and also 
hourly during the next 13 hrs at the end of the EC. In this study the PEFR was assessed with 
the mini-Wright peak-flow meter to measure bronchial obstruction. It is a suitable instrument 
for recording the PEFR after an exercise challenge. ЮЛ 1 
As reference values the PEFR on corresponding clocktime of the control day was taken. 
The % PEFR fall for the LAR after EC compared to corresponding clocktime on a control day 
was calculated as : 100% χ (PEFR at corresponding clocktime on control day - lowest PEFR 1-
13 hours after EC) / PEFR at corresponding clocktime on control day. 
FEVI was measured according the method of the ECCS using a dry spirometer 
(Schiller, Switzerland) in a group of asthmatic patients with reversible airflow limitation 
(n=19), in order to study the correlation between FEVI and PEFR measured.^ 
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Study-Design. 
When patients showed a PEFR fall £20% after EC compared to pre-exercise level they 
were asked to record their PEFR on a control day without exercise, with the same medication 
restrictions as on the exercise day, 2 days after the first EC. When patients after EC showed a 
PEFR fall of £20% on 3 or more consecutive time points 3-13 hours after EC compared to 
control day values, a second EC was performed after a minimal interval of 21 days and a 
maximum interval of 150 days. The second EC was performed with the same medication 
restriction as the first EC. In between these 2 exercise days the medication was kept unaltered. 
Nine at randomly chosen patients who did not show a PEFR fall £20% on 3 or more 
consecutive time points 3-13 hours after EC compared to control day values after the first EC 
compared to control day were rechallenged for the second time as in the patients with a LAR to 
EC. (The characteristics of the 9 patients without a LAR after EC are summarized in table 4-2) 
The protocol was approved by the ethical committee of the clinic. 
Table 4-2. Patient characteristics of the 9 patients without a LAR after EC. * Atopy is defined as 
three or more positive skin tests to common allergens. **Inh.:inhaled. 
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Statistical analysis. 
Statistical analysis was performed by using Student's t test for paired observations. Ρ 
values < 0.05 were considered significant. The decrease in PEFR after EC was also calculated 
from areas under the curve (AUC) 3for which the trapezoidal method was used. 12 AUC were 
3AUC descnbes the surface of the PEFR curve during the day, which is situated below the pre-exercise value line. 
It is a better method to follow decreases in PEFR in time compared to only one maximal PEFR fall. 
6 2 
compared by using the analysis of variance. The statistical method from Bland and Altman was 
used for assessing agreement between the two exercise days. 13 Repeatability was analyzed 
using repeatability coefficients.^ 
Results 
a. Correlation between PEFR and FEVI. 
Although extensive literature exists about a good correlation between PEFR 
measurements and FEVI measurements we have carried out a study to demonstrate this 
correlation ourselves, and to validate the use of PEFR recordings in the patient population 
referred to our hospital.^» Ю, 11 Therefore in a group of 19 patients with reversible airflow 
limitation on various occasions (seven times a day with an interval of 2 hours) PEFR and FEVI 
were registered (see figure 4-1.) A very close correlation (r=0.926) was observed, which 
indicated to us that PEFR values could be used to evaluate changes in airflow obstruction after 
exercise challenge. Analysis according to Bland and Altman showed a good repeatability and 
agreement. Based on these observations we have chosen for the registration of PEFR values 
after EC. In particular because most of the tested patients are well trained in using this piece of 
equipment adequately. 
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Figure 4-1. Correlation and regression equation between PEFR (L/min) and FE VI (L). Every 2 
hours between 09.00 am and 21.00 pm a PEFR and a FEVI were registered in 19 asthmatic 
patients with reversible airflow limitation. 
PEFR 
(L/min ) 
b. The EAR and LAR after EC in the investigated population. 
Of the 83 patients examined, 34 (41%) showed an EAR after EC (PEFR fall ^20% 
compared to the pre-exercise PEFR value). It appeared that 11 patients had a PEFR fall > 20% 
on 3 consecutive time points 3-13 hours after EC when compared to the corresponding 
clocktime on a control day. Of the 11 patients with a LAR after EC 8 patients had a dual 
response (EAR and LAR), 3 had an isolated LAR after EC. The 11 asthmatic patients with a 
LAR after EC were rechallenged after a minimal interval of 21 days and a maximal interval of 
150 days to test whether the occurrence of the LAR after EC was reproducible. 
The nine patients who served as controls did not develop a LAR to EC compared to 
corresponding clocktime on a control day nor did they show an EAR. 
64 
с. Reproducibility of the LAR after EC. 
Eight out of the 11 patients who experienced a LAR after EC showed again a PEFR fall 
220% on at least 3 consecutive time points 3-13 hours after EC compared to corresponding 
clocktime on a control day when they were rechallenged with exercise. Of those 8 patients who 
showed a reproducible LAR, 3 patients showed an EAR as well as a LAR after the first EC. In 
3 patients the dual asthmatic response proved to be reproducible. Three patients failed to 
develop a LAR after the second EC. The individual PEFR patterns of the control days as well as 
the EC days of those 11 patients are presented in figure 4-2. Patients 1, 2 and 4 clearly 
developed a reproducible LAR after EC. On more than 3 time points in patients 1 and 4 a PEFR 
fall 220% occurred 3-13 hours after EC. Patients 3, 5, 6, 7, and 8 also showed a clearly 
reproducible LAR, but with a different configuration of the figures. Nevertheless, also in these 
patients on more than 3 time points 3-13 hours after EC a PEFR fall >20% took place. On both 
control days a stable PEFR pattern was observed in patients 1, 2, 3,4, 6 and 7. Patients 5 and 
8 showed very instable control days. Nevertheless these patients should also be considered as 
having a reproducible LAR after EC. In patient 9 the change in PEFR gave the impression of 
the development of a LAR after EC. However after the second EC a LAR seemed to develop 
only at one time point after EC. Patient 10 had an early occurring reproducible LAR after EC 
with severe clinical symptoms, which required medical intervention. Patient 11 showed a PEFR 
fall 220% on the first EC day, but not on the second EC day. Therefore patients 9, 10 and 11 
should not be considered as having developed a reproducible LAR after EC. Taken together, 
when a PEFR fall 220% on three or more occasions 3-13 hours after EC in comparison with 
corresponding clocktime on a control day was used as a definition of a positive LAR after EC 
only 8 patients had a reproducible LAR after EC (patients 1-8). 
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Figure 4-2. Individual graphs of the 11 patients showing a LAR after EC. Both values of the 
control days and values of the exercise days are presented. Squares represent control days, 
open circles represent exercise days. ECl is the first exercise day, EC2 is the second exercise 
day. Arrows indicate a PEFR fall à20% after EC compared to corresponding clocktime on a 
control day. 
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Based on the combination of PEFR fall ¿20% in comparison with corresponding 
clocktime on a control day and the occurrence of such a fall on more than three consecutive time 
points 3-13 hours after EC we were able to discriminate between reproducible and not 
reproducible LAR's after EC. Table 4-3 summarizes the time points at which the LAR occurred 
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on the first and second occasion and the maximal % PEFR fall on both occasions, compared to 
the corresponding clocktime on a control day. 
Table 4-3. Comparison of the % PEFR fall for the EAR and LAR and the time point at which 
the maximal % PEFR fall for the LAR occurred when asthmatic patients with a positive LAR 
after EC were challenged with exercise on two different occasions. 
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From these data we could calculate that the mean maximal % PEFR fall for the LAR after EC on 
the first- and second exercise day; 48.4±20 % and 41.5±20 % respectively mean ± SD. The 
pre-exercise PEFR values on both control- and exercise days did not differ significantly. In the 
8 patients with a reproducible LAR after EC, the coefficient of variation in PEFR values of the 
first exercise day was 20.9 ± 12.5 and of the second exercise day 20.7± 13. The correlation 
coefficient of these variation coefficients was 0.9 (p<0.001). The coefficient of variation in 
PEFR values on the control days was 12.3±7.2 for the 8 patients with a reproducible LAR after 
EC whereas for the exercise days this coefficient of variation amounted 20.8±12.4 (p<0.05). 
The time points at which the LAR occurred after the first- and second EC did not show a 
correlation. 
In addition in 8 out of the 11 patients with a reproducible LAR after EC, AUC were 
calculated 3-13 hours after EC in order to study the reproducibility of the LAR after EC. A 
correlation coefficient of 0.8 (p<0.001) was found between areas under the curve for the LAR 
after EC for the first and second EC. The mean difference for AUC between the first and 
second EC for the 9 patients with a reproducible LAR was - 6300±44745 (mean ± SD) with 
95% confidence interval -43712 and 31113. We expect 95% of differences to be less than two 
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standard deviations. This is the définition of a repeatability coefficient adopted by the British 
Standards Institution. In our study all the 8 patients are satisfying this criteria. The sum of the 
differences squared is 1.433. l O ^ so the standard deviation of differences between the 8 pairs 
of repeated measurements is 1.598 .10^. The coefficient of repeatability is twice this; or 3.196 
.109. 
One of the asthmatic patients who experienced a reproducible LAR after EC (patient 
no.4.) has been challenged with exercise thereafter. In this patient the LAR after EC proved to 
be reproducible even after 11 months (see figure 4-3.). Also patient no 8 showed a reproducible 
LAR after 150 days. 
The 9 control patients who did not develop a LAR after the first EC also did not develop 
a LAR after the second EC. They did not show an EAR after the first EC and neither showed 
this reaction after the second EC. This supports the reliability of the methodology applied. 
Discussion 
In this study we have been able to demonstrate that the LAR after EC is a reproducible 
phenomenon when the LAR after EC is defined as: a PEFR fall ¿20% compared to the 
corresponding clocktime value on a control day on three consecutive time points 3-13 hours 
after EC. The EC was repeated 21-150 days after the first EC without changing the therapy of 
the patients in between. In 8 out of 11 asthmatic patients (73%) with a LAR after the first EC, a 
LAR occurred after the second EC. The LAR after EC was reproducible, although the time 
points did not correlate. The reproducibility was based on the graphical and statistical analysis 
of the individual PEFR data on the exercise days compared with the control days. Areas under 
the curve 3-13 hours after the first and second EC showed a good reproducibility and 
agreement. In addition the intrinsic variability of exercise and control days was assessed and it 
appeared that the exercise days differed significantly from both control days. From the 
individual graphs one may note that baseline airway calibre differs between the first- and second 
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Figure 4-3. Individual graphs of patient 4. EC 3 is done 11 months after respectively EC 1. 
Squares are control days, open circles are exercise days. Arrows indicate a PEFR fall >2Q% 
after EC compared to corresponding clocktime on a control day. 
P« 0, 3, 5, 8,10,15 l 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8,9,10.11,12,13 
minutes after EC I hours after EC 
control and exercise days. This likely is due to the fact that the first and second control and 
exercise day are 21-150 days apart. Moreover, a slight difference in the clinical situation of the 
patient may be responsible for differences in baseline airway calibre. However, on both 
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occasions the рге-exercise PEFR values of the control- and exercise days did not differ 
significantly. 
In this study PEFR measurements were used to document the change in airflow 
limitation, since it was demonstrated that these measurements closely correlate with FEVI 
measurements. Furthermore, all patients participating in this study were well trained in using 
the mini-Wright peakflow meter. As described by others this piece of equipment is suitable to 
register changes in ventilatory function accurately and reproducible when used 
adequately .9,10,11 
The question how to define a LAR after EC remains a controversial issue. In earlier 
papers we have addressed this point extensively.-*·'* The controversy in the literature about the 
LAR after EC is related to whether or not late responses to exercise really occur and how to 
properly define them. So far many studies dealing with the EAR and LAR after EC, have 
compared the PEFR fall after EC in relation to the рге-exercise PEFR value. 1.14-18 Due to 
diurnal variation later reports have advocated the use of a clockflme comparison on a control day 
without exercise instead.2-3 Although the definition is describing the LAR after EC more 
properly it still does not discriminate between a real and pseudo-LAR after EC. In a previous 
study we have therefore addressed this problem more closely and we have come to the 
definition used in this study i.e.: a PEFR fall ¿20% on three or more consecutive time points 
when compared with the corresponding clocktime value on a control day 3-13 hours after EC. 
Furthermore the graphs must clearly show a LAR. To our knowledge this definition of a LAR 
after EC is the most careful one used so far. 4 
Since the therapy regimen for the participating patients was kept unaltered between and 
before the two challenge occasions this study also argues strongly against the fact that the LAR 
after EC could be due to medication withdrawal.2>19 Furthermore, it extends the evidence that 
the LAR after EC is not a coincidence of a stable control day and an unstable EC day, since both 
were registered on two different occasions with an in between time period of 21-150 days. 
Corticosteroids have been demonstrated to suppress airway responsiveness to histamine 
and these drugs are effective in suppressing late responses to allergen provocation.20 it is 
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noteworthy in this study that LARs after EC do occur, despite the use of oral and/or inhaled 
corticosteroids. It could be possible that the dose of steroids was not high enough to prevent the 
LAR after EC, on the other hand it may be possible that the LAR after EC can not be prevented 
by steroids. In the latter case another pathofysiological mechanism than for the LAR after 
allergen provocation may be responsible for the LAR after EC. 
In the here studied asthmatic patients experiencing a LAR after EC the LAR pointed out 
to be reproducible in 73 % of the cases. From the presented data it is clear that, when strict 
criteria are applied for the LAR after EC, it is almost as reproducible as the LAR after antigen 
challenge.^ l¿2 Although the LAR after EC in itself was reproducible, the time points at which 
the maximal PEER fall occurred were not reproducible (see table 4-3.). One explanation for this 
discrepancy is that although the therapy regimen for the patients was kept constant throughout 
the study period a greater pan of the participating patients suffered from atopy (see table 4-1.). 
Since Davos is situated at high altitude (1560 m) the concentration of airborne allergens is low. 
Therefore patients arc less exposed which may lead to lesser complaints of airway obstruction 
and improvement of PEFR values. This explanation is supported by the finding that the skin 
reactivity to a panel of common allergens decreased considerably after a stay of 3 months in 
Davos.23 Since Davos is surrounded by fields of grass as well as pollinating deciduous trees 
the skin reactivity towards these allergens did not change. Notwithstanding this decrease in 
allergen load, the LAR after EC occurred, was reproducible and did not show great seasonal 
variation. The patients mentioned in this study were tested inside after an overnight sleep and 
were not allowed to go outdoors. 
Taken together, the LAR after EC may be diagnosed on the basis of the PEFR fall 
measurements compared to control day values on three or more time points 3-13 hours after 
EC. Based on these criteria the LAR after EC proved to be a reproducible phenomenon in the 
majority of the tested patients. For this reason we feel the LAR after EC is a reproducible 
phenomenon. 
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Abstract 
In order to study whether an inflammatory component could be involved in the late asthmatic 
reaction (LAR) after exercise challenge (EQ, changes in bronchial hyperreactivity to histamine 
(BHR), Inflammatory cell number» and derived mediatori In peripheral blood at fixed time 
points before, during and after the LAR after EC were analyzed. Nine asthmatic patients with a 
reproducible positive LAR after EC and three asthmatic patients with a reproducible negative 
LAR after EC were incorporated in the study. It appeared that BHR to histamine increased 24 
and 48 hours after EC, both in most of the patients of the group with a positive LAR and in the 
group with a negative LAR. No consistent changes were observed in neutrophil, eosinophil and 
basophil numbers in peripheral blood as well as serum eosinophil cationic protein levels and 
serum histamine levels in the group with a positive LAR after EC. Therefore from this study it 
may be concluded that if an inflammatory component is involved in the LAR after EC it is not 
reflected by the here measured parameters. 
Introduction 
After exercise challenge (EC) asthmatic patients may show an early asthmatic response 
(EAR) and/or a late asthmatic response (LAR). The EAR is expressed as the fall in peak 
expiratory flow rate (PEER) or in forced expiratory volume in 1 second (FEVI) and appears 
within 10 minutes after EC, reaches a maximum after 20-30 minutes, and disappears normally 
within 1-3 hours. A LAR after EC can occur after recovery from the EAR and usually starts 3-
12 hours after the EC, decreases in severity after 12 hours and disappears spontaneously within 
24 hours. In several studies the existence of the late asthmatic reaction (LAR) after exercise 
challenge (EC) has been well established, especially when lungfunction changes at the LAR 
after EC are compared to corresponding clocktime on a control day without exercise [1]. 
The pathophysiological mechanisms behind the early and late asthmatic reaction after EC 
have been extensively investigated. Various mechanisms have been postulated: hypoxia [2], 
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hypercapnia [3], lactic acidosis [4], stimulation of nasopharyngolaiyngeal receptors [5], airway 
cooling during exercise [6-9], airway water loss during exercise [10], condensation of water on 
airways during exercise [11], a slow onset of adrenaline release and decreased 
catecholaminergic effectiveness [12]. However, all these hypothesized etiological factors have 
been criticized [13-17]. 
In this study we investigated whether an inflammatory component, reflected by changes 
in bronchial hyperreactivity (BHR) to histamine and changes in inflammatory cell numbers in 
the circulation and changes in serum eosinophil cationic protein and serum histamine levels 
would reflect events taking place during a LAR after EC. 
Patients and methods 
Patients 
All patients with bronchial asthma had a documented bronchial hyperresponsiveness, 
measured according to Hargreave et al. and expressed as the concentration of inhaled histamine 
which results in a 20% decrease of FEVl (PC20 < 8 mg/ml) [18]. Asthmatic and COPD 
patients were classified according to ATS criteria. [19] In COPD patients the FEVl reversibility 
after 0,4 mg inhaled salbutamol was less than 20% of the predicted value in contrast to 
asthmatic patients. 
Throughout the study period all patients had to submit to concomitant medication rules. 
The patients had to stop inhaled bronchodilators 8 hours before EC and during the control day. 
Sodium cromoglycate had to be stopped 24 hours before the exercise test and during the control 
day. Any type of oral bronchodilator had to be stopped at least 48 hours before the start of the 
EC and during the control day. The dose of oral and inhaled steroids was kept constant. All 
patients on steroids were using this treatment for at least 3 months. Patients did not stop 
smoking during the study. Their smoking habits remained unaltered during the study period. 
Informed consent was obtained from each of the patients. The characteristics of the patients 
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who participated in this study with a reproducible positive and negative LAR after EC are 
summarized in table 5-1. 
Table 5-1. Patient characteristics of the patients with a reproducible positive and negative LAR 
after EC. 
Patient no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Age (yeera) 
19 
26 
22 
41 
54 
66 
69 
55 
63 
Negative reproducible L 
Patient no. 
10 
11 
12 
Age (years) 
64 
62 
46 
Sex 
Female 
Female 
Female 
Female 
Female 
Male 
Female 
Female 
Female 
^R after 
Sex 
Male 
Male 
Male 
Olagnoee 
Asthma 
Asthma 
Asthma 
Asthma 
cero 
cero 
coro 
coro 
coro 
EC. 
Diagnose 
cero 
Asthma 
cero 
FEV1(% pred.) 
71 
90 
SS 
71 
66 
48 
52 9 
52 
68 
FEV1(% pred.) 
39 
82 3 
57 5 
PC 20 (mg/mi) 
< 0 03 
1 8 
0 35 
0 95 
0 1 
0.32 
< 0 0 3 
0 05 
0 35 
Atopy 
+ 
+ 
+ 
+ 
+ 
+ 
Smoker 
-
+ 
+ 
. 
. 
PC 20 (mg/mi) 
0 08 
0 86 
0 04 
Atopy Smoker 
Yes 
Yes 
Yes 
Steroids 
po ,inh 
po ,inh 
inh 
po ,inh 
po 
ρ o ,inh 
mh 
po 
ρ o .inh 
Steroids 
oral 
inhalation 
inhalation 
Exercise Challenge (EC) 
All ECs were performed on a bicycle ergometer (Erich Jäger, Würzburg, Germany). 
The workload in Watts was 80% of the predicted maximum workload. The predicted maximum 
workload was calculated according to Eggleston [20]. Exercise was performed for 8 minutes 
during which a heart-rate of 90% of the predicted maximum was reached. During the EC the 
heart-rate was measured by a Siemens Sirecust 341 monitor (Siemens, Germany). The relative 
humidity of the ambient air was 20-40%, the room temperature was 20-23° Celsius, both on the 
control and the exercise days and were both measured with the Hygrotest 6200 (Quarz AG, 
Zürich, Switzerland). The humidity and room temperature were allowed to variate 10% and 20C 
respectively during the control- and exercise day for each patient. During the 8 min. bicycling 
the patients wore a noseclip. 
Peakflow measurements. 
PEFR was measured with the mini-Wright peakflow meter. The same peakflow meter 
was used at each occasion. The best of three measurements was recorded. Before and after each 
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daily recording of peakflow rates, meters were checked and cleaned by the lung function 
technician. PEFR was recorded on the control day at t=0 (09.00 a.m.) and during the first 13 
hrs after t=0 at hourly intervals; on the exercise day PEFR was recorded at t=0 hour (= pre-
exercise PEFR) and 1, 3, 5, 7, 10, 15 and 30 minutes afterwards, and also hourly during the 
next 13 hrs at the end of the EC. 
As reference values the PEFR on corresponding clocktime of the control day was taken. 
The % PEFR fall for the LAR after EC compared to corresponding clocktime on a control day 
was calculated as : 100% χ (PEFR at corresponding clocktime on control day - lowest PEFR 1-
13 hours after EC) / PEFR at corresponding clocktime on control day. A LAR is defined as a 
¿20% fall in PEFR compared to corresponding clocktime on a control day on more than one 
time point 3-13 hours after EC. 
In this study only patients were included who showed a reproducible LAR after EC 
compared to control day. The reproducibility of the LAR after EC has been extensively 
documented elsewhere [21]. 
PC20 measurements 
Bronchial hyperresponsiveness (BHR) was measured according to Hargreave et al. and 
expressed as the concentration of inhaled histamine in mg/ml which results in a 20% decrease of 
FEV1 [18]. PC20 was determined before EC and 1,24 and 48 hours after EC. 
Blood cell numbers 
At various time points blood samples were collected (see figure 5-1.) in EDTA. These 
samples were analyzed for eosinophil, neutrophil and basophil numbers by means of an 
automated cell counter (Technicon A 6000, USA). 
Serum-eosinophil-cationic protein (s-ECP) and histamine 
At the same time points as blood was collected for blood cell analysis 3-5 ml of blood 
was collected and allowed to clot at room temperature for 60 minutes. Then serum was collected 
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and stored in fractions at -20° С until analysis. s-ECP was determined by RIA (Pharmacia 
Diagnostica AB, Uppsala, Sweden), exactly according to the manufacturer's instructions. Also 
histamine was determined by RIA (Immunotech, Marseille, France) exactly according to the 
manufacturers instructions. For the determination of s-ECP and histamine freshly thawed 
fractions of serum were used. s-ECP values are expressed in μ ^ and histamine values are 
expressed in nmol/L. 
Study-Design. 
Only patients who showed a reproducible LAR after EC were enrolled in the study. 
Nine of those asthmatic patients performed a third EC with the same medication restriction as on 
the control and exercise days. Before exercise challenge took place an iv catheter was 
introduced in an antebrachial vein. At various time points before, during and after EC, PClO's 
for histamine and blood collection took place. This is outlined in figure 5-1. This study design 
was also used for the 3 asthmatic patients with a reproducible negative LAR after EC. They 
underwent the same procedure as the patients with a reproducible positive LAR. 
Statistical analysis 
PCiO's for histamine, blood cell numbers, s-ECP, and serum histamine were compared 
at each time point with the pre-exercise value as a reference by means of a paired student's t 
test. The patient group with a positive reproducible LAR was compared with the one without a 
LAR for PC20's for histamine, blood cell numbers, s-ECP, and serum histamine levels using 
analysis of variance. 
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Figure 5-1. Study design 
PEFR 
% decrease 
¡η relation to 
control day 
100% _ 
24 hours 48 hours 
Tune alter EC 
B,C В В В,С В,С 
В,С 
С : Bronchial challenge В: Blood sampling 
Results 
In this study 9 patients with a reproducible positive LAR after EC and 3 patients without 
any reaction (neither EAR or LAR) after EC participated. Four patients (no.l, 2,3,4 ) showed 
a reproducible positive EAR and LAR after EC. Five patients (no 5, 6, 7, 8, 9) showed an 
isolated LAR after EC. The other patients (no. 10, 11 and 12) showed a reproducible negative 
EAR and LAR after EC. As described in the materials and methods section of those patients 
changes in PC20 for histamine, changes in neutrophil, eosinophil and basophil counts in 
peripheral blood and changes in s-ECP and serum histamine were recorded before, during and 
after EC. The individual data are plotted in table 5-2 and figure 5-2. 
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Table 5-2. PC20 to histamine in mg/ml before, at 1 hour, at 24 and 48 hours after EC in the 
patient group 
LAR + 
1 
2 
3 
4 
5 
6 
7 
8 
9 
LAR -
10 
11 
12 
with a positive a 
T=0 
< 0.03 
0.6 
0.58 
4.00 
0.038 
0.45 
0.5 
0.4 
0.35 
T=0 
0.085 
5 
0.42 
ind negative LA 
T=1 HR 
< 0.03 
0.6 
0.67 
1.83 
0.65 
0.06 
0.5 
0.19 
0.57 
T»1 HR 
< 0.03 
7 
0.60 
R after EC. 
T=24 HR 
< 0.03 
0.25 
0.33 
0.54 
0.07 
0.38 
0.33 
0.21 
• 
T=24 HR 
< 0.03 
3 
0.09 
T=48 HR 
< 0.03 
6.5 
0.27 
• 
0.037 
0.32 
0.25 
0.11 
* 
T=48 HR 
< 0.03 
5 
0.05 
Changes in BHR before, during and after a LAR after EC. 
Only in one out of the 4 patients with a reproducible EAR and LAR after EC a clear 
decrease in BHR was observed (patient no. 4). In the S patients with a reproducible isolated 
LAR after EC patient no.6, showed a decrease in BHR, whereas patients no. 5 and 9 showed 
an increase in BHR at 1 hour after EC. In the patient group with a reproducible negative LAR 
after EC 2 patients (no. 11 and 12) showed a decrease in BHR after 1 hour after EC. At 24 
hours after EC an increase in BHR was observed in patients no. 2, 3, 4, 5, 6, 7 and 8 
compared with the pre-exercise BHR. However in the patient group with a negative 
reproducible LAR after EC also an increase in BHR at 24 hours was present in all patients 
compared to the pre-exercise BHR value. At 48 hours after EC most of the investigated patients 
showed a further increase in BHR to histamine as compared with the pre-exercise value in BHR 
and the BHR value at 24 hours. Thus, although most of the patients with a reproducible LAR 
after EC showed an increase in PC20 for histamine at 24 and 48 hours after EC, the control 
patients showed an identical reaction pattern, (table 5-2) 
Changes in neutrophil, eosinophil and basophil cell numbers before, during and after a LAR 
after EC. 
a. Neutrophils 
In the patient group showing an EAR and LAR after EC there seems a tendency in the 
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neutrophil cell number to increase after the EAR (between IS minutes and one hour). In the 
patient group showing an isolated LAR after EC there hardly seems a change in neutrophil cell 
number as is the case in the patient group showing a negative LAR after EC. 
b. Eosinophils 
In all patient groups there was no clear consistency in the eosinophil cell number to increase or 
decrease. Also at 24 and/or 48 hours after EC there was no clear increase in the eosinophil cell 
number in the patients who showed a positive reproducible LAR after EC. 
с Basophils 
The basophil counts did not change greatly during and after the LAR in all investigated groups. 
Changes in s-ECP and serum histamine levels after a LAR after EC. 
The control group (patient no. 10, 11 and 12) did not show striking changes in s-ECP 
and serum histamine levels. 
In the patient group with a positive reproducible EAR and LAR after EC (patients no. 1, 
2, 3, 4) in patient no. 1 a clear increase in s-ECP as well as serum histamine at IS minutes 
whereas increase were present at 6 and 24 hours. In patient no.2 a small rise in serum histamine 
just before the LAR after EC occurred; s-ECP remained unchanged. In this patient the EAR was 
not reflected by changes in serum histamine or s-ECP. In patient no. 3 a small increase in s-
ECP during the EAR after EC and a similar increase in s-ECP at 48 hours after EC was 
observed; during the LAR no changes occurred. In patient no. 4 serum histamine levels 
remained totally unchanged during and after EC. The s-ECP levels showed similar findings. 
Thus in the patient group who showed a reproducible EAR and LAR after EC (patients no. 1, 
2, 3 and 4) no clear changes in serum histamine or s-ECP levels in relation to either the EAR or 
the LAR were observed. In one patient (no. 1) serum histamine and s-ECP rose during the EAR 
and remained fairly constant thereafter, whereas in another patient (no. 4) there seemed to be a 
coincidence between changes in these parameters and the occurrence of the LAR. 
In the patient group who showed an isolated LAR after EC (patients no. S, 6, 7, 8 and 
9) no changes in serum histamine and s-ECP levels were observed in patients no. S and 6. In 
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patient no. 7 an inconsistent pattern with respect to s-ECP was observed. In contrast in patient 
no. 8 the increase in s-ECP and serum histamine levels correlated remarkably well with the 
occurrence of the LAR after EC. In patient no. 9 an increase in serum histamine levels seemed 
to parallel the LAR after EC, whereas s-ECP levels did not change. 
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Figure 5-2. PEFR pattern in l/min after EC (open circles) and on a control day without exercise 
(open squares). Neutrophil, eosinophil and basophil counts in peripheral blood are expressed χ 
10 6/L. Histamine levels (black squares) are expressed in nmol/1, s-ECP levels (open squares) 
are expressed in ug/1 
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Discussion 
Since pathogenetic explanations given for the occurrence of the LAR after EC have been 
unsatisfactory so far, we have tried to find evidence for the involvement of an inflammatory 
reaction in the LAR after EC. In a previous study the appearance of neutrophil chemotactive 
activity in the circulation has suggested inflammation to be of some importance for the LAR 
after EC [22]. Airway inflammation is an important etiological factor in the LAR after allergen 
inhalation [23] and in the LAR in occupational asthma [24]. The LAR after allergen inhalation 
may be prevented by the use of glucocorticosteroids (GC) [23,24]. This seems also to be the 
case in LAR after EC and gives further support for the hypothesis of an inflammatory basis for 
the LAR after EC [1, 25, 26]. In our study, patients continued using steroids. But the GC did 
not prevent a LAR to occur in 9 of the 9 asthmatic patients studied, although they used the 
steroids for at least 3 months before starting the study. Therefore, either the actual prevalence of 
the LAR after EC may be greater than found in our study or the role of inflammation in the LAR 
may be of less importance after EC than in the other LARs mentioned above [1]. 
In this study we tried to gather evidence that inflammation would be involved in the 
LAR after EC. As parameters reflecting an inflammatory component to be involved bronchial 
hyperreactivity to histamine, changes in inflammatory cell numbers and changes in s-ECP and 
serum histamine levels were quantitated before, during and after the LAR after EC. 
In accordance with the LAR after allergen seemed the increase in В HR to histamine 24 
and 48 hours in the LAR after EC. However, also the control group showed a similar tendency. 
Therefore these findings do not allow us to draw conclusions. In contrast to the LAR after 
allergen challenge where 24 hours after challenge an increase in eosinophil counts and an 
increase in s-ECP may be observed, no such changes were observed after the LAR after EC. 
Also in the majority of the cases studied the changes in serum histamine levels did not 
coincidence or precede the occurrence of the LAR after EC. Although in some cases changes in 
serum histamine and s-ECP levels seemed to correlate with the occurrence of an EAR or LAR 
after EC. The results as a whole show too little consistence to allow any conclusions. Most 
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likely changes in the peripheral compartment do not reflect changes in the lung. On the other 
hand the continuous intake of steroids may have influenced our results. However, for clinical 
reasons it was not possible to withdraw this treatment from the patients. Therefore further 
studies, most closely to the lung compartment are necessary to unravel some of the pathogenetic 
mechanisms behind the LAR after EC. 
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Abstract 
A double-blind crossover study was carried out to determine the effect of nedocromil sodium on 
the dual asthmatic response to exercise challenge. Nineteen patients with a late response (8 
minutes on a bicycle ergometer) to exercise on a screening day were randomly assigned to 
treatment order with 4 mg nedocromil sodium or a matched placebo aerosol. Exercise challenge 
was performed on two study days, when two puffs of test medication were inhaled 30 minutes 
before commencing exercise. Peak flow was measured 10 and 5 minutes before exercise to give 
the mean pre-exercise baseline, and at 1,3,5,7,10,15,30 and 60 minutes after exercise and each 
hour thereafter for up to 13 hours post-exercise. Treatment effects on the late (4-13 hour) 
response were compared primarily from the maximum % fall in peak flow from pre-exercise 
values. This was reduced significantly by pretreatment with nedocromil sodium compared to 
placebo (12.4% vs 25.8%; p<0.01). The early (1-60 minute) reaction seen in 12 of the patients 
was also significantly reduced by nedocromil sodium (p<0.01). Exercise-induced changes 
calculated from equivalent diurnal peak flow values showed a smaller late asthmatic response 
but the protective effect of nedocromil sodium was still evident. 
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Introduction 
Asthmatic patients who react with bronchoconstriction after exercise challenge may show an 
early asthmatic response (EAR) and/or a late asthmatic response (LAR)[1]. During the EAR, 
lung function starts to deteriorate within 10 minutes after exercise, shows a maximum fall after 
20-30 minutes and generally disappears within 1-3 hours. A LAR can occur, after partial or 
complete recovery from the EAR, and begins 4-13 hours after exercise, decreasing in severity 
after 12 hours and normally resolving within 24 hours. The incidence of LARs due to exercise 
is disputed[2,3] but the development of these reactions has been linked to release of mast cell-
derived mediators and possible inflammatory changes in the lung[4]. Recent reports have 
increased the controversy over the mechanism of exercise-induced bronchoconstriction[5]. 
Changes in serum levels of neutrophil chemotactic factors after exercise were not found to 
correlate with the severity of bronchoconstriction[6] and examination of mediators in 
bronchoalveolar lavage samples after exercise challenge suggested no involvement of airway 
mast cells in the EAR[7]. In a study by Rubinstein et al[8] five out of six patients who had 
shown a dual response to exercise challenge suffered a similar 'late' decrease in FEV1 on a no-
exercise control day, suggesting the LAR might be caused by diurnal variation of airway calibre 
in conditions of restricted bronchodilator therapy. 
Many of the drugs employed in asthma therapy are effective against exercise-induced 
asthma[6,9] but in general only the EAR has been studied. 
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In this study we examined the effect on both EAR and LAR after exercise of a new topical anti-
inflammatory asthma treatment, nedocromil sodium (Tilade)[10]f which is known to prevent 
both phases of the dual asthmatic response to bronchial antigen challenge as well as the 
immediate bronchospasm provoked by exercise challenge[l 1]. 
We measured bronchoconstriction primarily by the fall in peak expiratory flow rate (PEFR) 
from the baseline level recorded prior to each exercise challenge, but a no-exercise control day 
was also included to investigate the possible influence of diurnal variation on the LAR. 
Material and Methods 
Study Design 
This was a double-blind, randomized, placebo-controlled crossover trial to study the effect of 
pretreatment with nedocromil sodium on the EAR and LAR following exercise challenge in a 
group of patients known to develop a LAR. Subjects were selected on an initial screening day 
from patients with a documented history of asthma or chronic obstructive pulmonary disease 
(COPD)[12]. PEFR (1/min) was measured, using a mini-Wright peak flow meter and recording 
the best of 3 measurements, at 10 and 5 minutes before commencing exercise challenge. The 
mean of these two pre-exercise readings was taken as the baseline PEFR value for that day. 
Exercise challenge was carried out on a bicycle ergometer (Erich Jager, Wurtzburg, Germany) 
with the workload at 80% of the predicted maximum, adjusted for age, sex and height[13]. 
102 
Exercise was performed for 8 minutes, the workload being reduced if necessary, during which 
time a heart-rate of 90% of predicted maximum was achieved. Heart-rate was measured by a 
Siemens Sirecrust 341 monitor (Siemens, Germany). During bicycle exercise each patient wore 
a nose-clip. Ambient conditions were measured using a Hygrotest 6200 (Quartz AG, Zurich, 
Switzerland): relative humidity was 20-40% and room temperature 20-23oC. Variations of 10% 
and 20C respectively were permitted during any one patient study day. Using the same meter for 
all tests, PEFR was measured at 1, 3,5, 7,10, 15, 30 and 60 minutes after the end of exercise, 
and again at hourly intervals up to 13 hours after challenge. A positive asthmatic response to 
exercise was defined as >15% fall in PEFR from the pre-exercise baseline value. The asthmatic 
response was defined as an EAR at time points from 1-60 minutes after challenge and as a LAR 
when the >15% fall from pre-exercise PEFR occurred during the period 4-13 hours after 
exercise challenge.4 Only patients who developed a LAR (with or without an EAR) were 
randomized to test treatment 
Medication was restricted on all exercise challenge days: inhaled bronchodilators were not to be 
used for a period of 8 hours before exercise, nor sodium cromoglycate for a 24-hour period. 
Use of oral bronchodilators was to be avoided during the preceding 48 hours, and 
corticosteroid usage was to have been stable for 3 months and be maintained at a constant level 
throughout the study period. 
On test treatment study days the same exercise challenge procedure was carried out. Thirty 
minutes before starting exercise, test treatment was taken by inhalation of two puffs of 
medication from an aerosol can that contained either nedocromil sodium (total dose 4 mg) or a 
matching placebo. An additional PEFR measurement was taken one minute before the test 
treatment. Treatment order was randomly assigned by coding sheet and all study days were 
separated by an interval of 4-12 days. 
4The 15% level of PEFR fall was choosen to include also 2 patients who had clear clinical symptoms of a LAR 
after exercise challenge, but showed a PEFR fall of resp. 18.3 and 19.2% compared to baseline value. All of the 
other patients had a PEFR fall >20%. Fuithermore it is noteworthy to mention that this study was the fust study 
we performed in the investigation of the LAR after exercise challenge. 
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To investigate the influence of diurnal variation on the LAR to exercise challenge, PEFR 
readings were additionally taken at the same times of day on a separate control day, when all 
conditions were, similar to the screening day except that no exercise challenge was carried out. 
The LAR expressed as % fall in PEFR from the equivalent 'clocktime' PEFR on this no-
challenge control day was also used to examine treatment effects in relation to diurnal variation 
of PEFR readings, in a secondary assessment made for comparative purposes. 
Patients 
Out of 86 patients screened, 19 individuals (22%) developed a LAR following exercise 
challenge and were subsequently randomized to test treatment. Seven of these responders 
showed an isolated LAR whilst the remaining 12 had a dual reaction. (A further 21/86 patients 
showed only an EAR.) 
The characteristics of the 19 patients who took part in the drug study are summarized in Table 
6-1. Nine patients were randomized to the nedocromil sodium/placebo treatment order group 
and 10 to placebo/nedocromil sodium, the two groups being well-matched. 
Seven patients were male and 12 female, with an age range from 17.8 - 62.5 years. Thirteen 
subjects were classified as bronchial asthmatics and six as COPD patients 12, the latter 
distinguished by FEV1 reversibility <20% predicted after inhalation of 0.4 mg salbutamol. All 
showed hyperresponsiveness to inhaled histamine (PC20 < 8 mg/ml)14. Five patients were 
tobacco smokers and continued their usual smoking pattern during the study. After withdrawal 
of concomitant medication all patients had a PEFR value ¿55% predicted before commencing 
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exercise challenge. Informed consent to the trial was obtained from all patients, or from the 
parents of those who were under-age. 
Statistical Methods 
Parametric statistical methods were applied throughout the analyses. Analysis of variance with 
patient, order and treatment as factors was used to analyze PEFR differences from baseline at 
each time point. 
The PEFR data were also summarized for each patient as area under the curve (AUC) of the 
time course and maximum % decreases from baseline, again using analysis of variance. These 
summary data were regarded as the primary variables, with PEFR changes at individual time 
points defined as secondary variables. Two-tailed tests were used throughout, with a 
significance level of 0.05. 
Diurnal PEFR changes based on equivalent 'clocktime' control data are presented for 
comparative reference only since the stated purpose of the study was to compare the effects of 
nedocromil sodium and placebo on the fall in PEFR after exercise. 
Patients who failed to show an EAR to exercise on the screening day were excluded from 
analyses of the EAR but included in the LAR analysis. 
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Results 
All 19 patients completed the study treatment days as well as the screening day. No unusual 
symptoms were reported during the study. Each exercise challenge was carried out at the same 
time of day for each patient except in one case (patient 36) when the two test treatment 
challenges commenced 40 minutes later than on the screening day. Screening day results are 
detailed in Table 6-2. All the patients showed a fall from baseline PEFR >18% during the 
period 4-13 hours after exercise challenge (LAR). Twelve patients had recorded a similar early 
reduction in PEFR in the period from 1-60 minutes after exercise (EAR) and were therefore 
included in analysis of the EAR. Seven patients (1, 3, 4, 8, 12, 34, 35) did not show a 
sufficient fall in PEFR in the first hour after exercise and were excluded from analysis of the 
EAR. 
Five patients (numbers 2, 4, 13, 34, 35) used bronchodilators on the screening day. All 
showed a (late) PEFR reduction of 20% or more (Table 6-2). Except for patient 34, 
bronchodilator use occurred only at 9 or 10 hours post-exercise, and was repeated at the 
identical times on the two test treatment days; the results of these four patients were included in 
the analysis. Patients 34 and 37 used bronchodilators on the placebo study day but not on the 
nedocromil sodium day and their data were analyzed only up to the point of medication (5 
minutes and 5 hours post-exercise, respectively). Since LAR data from patient 34 were 
excluded for this reason, 18 patients in total were analyzed for the post-exercise LAR. Using 
paired t-tests (sample size =19) pre-exercise baseline PEFR values showed little variation on 
the three challenge days: (means ± standard deviations of 366.1 ± 68.8; 369.2 ± 73.6 and 
371.7 ± 70.6 L/min for screen day, active and placebo treatment days respectively). On both the 
treatment days, PEFR values recorded just prior to aerosol treatment (at 31 minutes before 
exercise and 21-26 minutes before the baseline PEFR measurements) were rather lower than 
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baseline (p<0.05): means of 355.0 ± 71.8 and 355.8 ± 67.5 L/min for nedocromil sodium and 
placebo pre-treatment PEFR values, respectively. 
Results of the analyses carried out on absolute differences in PEFR (L/min) from the pre-
exercise baseline at each test treatment challenge are summarized in Tables 6-3 and 6-4. PEFR 
changes on the EIA (no treatment) screen day are included with the treatment group results for 
reference only. For the EAR (Table 6-3) the maximum % fall in PEFR was significantly less 
(p<0.01) with nedocromil sodium (13.2%) than with placebo (36.6%). The AUC was also 
significantly better (p<0.01) with nedocromil sodium during the EAR. Significant differences 
(p<0.05 - p<0.01) in favour of nedocromil sodium continued to occur at individual time points 
up to 11 hours post-exercise (Table 6-4). AUC for the LAR showed a strong trend in favour of 
the active treatment, however it should be noted that only the nedocromil sodium treated patients 
fully recovered their baseline levels of PEFR following resolution of the EAR. The maximum 
% fall in PEFR during the LAR (Table 5-4) was reduced significantly (p<0.01) by pretreatment 
with nedocromil sodium (12.4%) compared to placebo (25.8%). Individual patient results for 
maximum fall in PEFR after exercise on the (no- treatment) screen day and following active 
(nedocromil sodium) and placebo test treatments are presented as % fall from pre-exercise 
baseline (Table 6-5) and again as % predicted normal PEFR (Table 6-6). 
To allow for the influence of diurnal variations in PEFR, measurements taken at the equivalent 
'clocktimes' on a separate, no-challenge control day were also used as baseline values for 
calculation of maximum % fall in PEFR during the LAR. These values are shown (Table 6-7) 
for comparative purposes but were not used in the statistical comparison of nedocromil sodium 
and placebo treatment effects on EIA. The group mean maximum % fall in PEFR 4-13 hours 
after exercise as calculated from the 'clocktime' norm was approximately 12% lesser throughout 
than the fall from the pre-exercise baseline. Consequently the number of LARs was reduced; 
however the overall group mean % fall in PEFR on the screenday still reached 22.9%, with 
10/18 patients showing an unequivocal LAR äl9.0% fall in PEFR). This diumally-adjusted 
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LAR was considerably reduced by placebo treatment (mean 11.6% fall in PEFR) and ablated by 
nedocromil sodium (mean increase in PEFR of 1.6%). 
Discussion 
This study set out to investigate the preventive effect of nedocromil sodium on exercise-induced 
bronchoconstriction in patients showing a late phase reaction (LAR) 4-13 hours after exercise 
challenge. The very existence of dual reactions to exercise in patients with airflow limitation 
remains in itself a subject of continuing debate and the prevalence of LARs after exercise 
challenge has been variously reported as 2%-60%[l, 15,16]. 
It was therefore important to make sure the response we were measuring was real and not 
artifactual. The generally accepted method of assessing the effects of bronchial challenge on 
lung function is to compare serial measurements after challenge against the baseline level 
measured prior to challenge. In the case of exercise-induced lung function changes, the 
response may be influenced by many different factors and the mechanism of airway obstruction 
has yet to be elucidated[17-19]. Current evidence suggests that diumal factors may have a 
strong influence on the post-exercise asthmatic response and several lines of evidence are in 
favour of comparing lung function after exercise with the corresponding 'clocktime' values on a 
control day[8,15]. Our results support this view since both incidence and severity of LAR after 
exercise challenge were reduced when the diurnal rhythm was taken into account in this way. 
At the same time, this study further substantiates the evidence for the existence of both an EAR 
and a LAR after exercise challenge in patients with airflow limitation. From a group of 86 
asthmatic patients who underwent exercise challenge, 33 (38%) developed an EAR, measured 
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as fall from pre-exercise PEFR. Using the same pre-exercise baseline, a total of 19/86 patients 
(22%) developed a LAR. Only 12/86 of these patients (14%) had a dual response, whilst 7/86 
(8%) had an isolated LAR. Isolated EAR thus occurred in 21/86 (24%) of the patients. These 
LAR incidence figures based on the 'standard' fall in PEFR from pre-exercise baseline may 
have been increased because we looked for LAR in all the patients rather than examining a 
subgroup known to develop an EAR to exercise: this could be important as 7 out of 19 LAR 
patients had no preceding EAR. The incidence of LAR was reduced by half when taken as the 
fall in PEFR from the corresponding 'clocktime' value on a no-exercise control day. 
Using this more valid criterion as a baseline measure only 10 of the original 86 patients ( 11.6%) 
showed a LAR in response to exercise. Even on this basis, however, the incidence of exercise-
induced LAR was considerable and cannot be swept aside. It is possible that our patients were 
not a truly representative population since they suffered from severe asthma and COPD, such 
that they had to continue their daily corticosteroid therapy during the study. Nevertheless, some 
were able to develop a LAR after exercise challenge, which could perhaps indicate that the 
steroid dose was insufficient It was interesting to find that all the (6) COPD patients challenged 
had a LAR after exercise: at present we have no adequate explanation for this. 
In view of the fact that the patients maintained their corticosteroid therapy throughout the trial, 
we were interested to find that nedocromil sodium not only effectively blocked the EAR and the 
LAR after exercise challenge but that the effect against the LAR was stronger when this was 
measured from the diurnal equivalent rather than the pre-exercise PEFR, A placebo effect was 
evident, this too being stronger on the LAR, which introduced the possibility of psychological 
influences on this response, in addition to doubts about its reproducibility. We have partly 
answered this question by showing the LAR following exercise challenge to be a highly 
reproducible phenomenon in repeat tests performed 2-13 weeks after the first challenge (data 
not yet published). The strongly protective effect of nedocromil sodium against the LAR 
resulting from exercise challenge appears to tie-in with the efficacy of this compound in 
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preventing the dual asthmatic response to bronchial allergen challenge[20] and suggests the 
involvement of an inflammatory component in the exercise-induced LAR also. 
It is well-accepted, however, that the pathogenesis of EIA is multifactorial. One major 
component is considered to be increased water loss from the airway lining fluid, creating a 
hyperosmolar environment in the bronchial mucosa[21] which could be a stimulus for mediator 
release from resident cells such as mast cells[4]. 
The inhibitory activity of nedocromil sodium on mucosal mast cells and other resident cells of 
the airways would again fit in with this explanation[22,23], which has been countered, 
however, by the suggestion that exercise increases bronchial obstruction in asthmatics through 
congestion of the microvasculature[19]. This mechanism also could be moderated by 
nedocromil sodium, which is known to affect microvascular leakage and neurogenic 
inflammation in the airways[24]. 
Whilst both the pathogenesis of EIA and the mechanism of actíon of nedocromil sodium remain 
subjects for investigation, our present study confmned that a proportion of patients with severe 
asthma and COPD do develop a LAR after exercise challenge and that both this and the 
immediate EAR are effectively inhibited by pretreatment with a single dose (4 mg) of 
nedocromil sodium. 
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Table 6-1. Patient Characteristics at Admission 
Variable Mean Value/Frequency (n=19) 
Age (years) 
Sex 
Diagnosis 
Histamine PC20 (mg/ml) 
Baseline FEV1: (L) 
(% predicted) 
FVC:(L) 
(% predicted) 
Atopic status 
Smokers 
Cunent therapy: 
Antihistamine 
Inhaled corticosteroid 
Oral corticosteroid 
Theophyllines/Xanthines 
Inhaled bronchodilators 
Oral bronchodilators 
Sodium cromoglycate 
37.5 ± 13.6 
7 males/12 females 
13asthina/6COPD 
1.4 ± 0.3 
2.47 ± 0.77 
78.1 ± 24.3 
3.86 ± 0.93 
99.3 ± 16.7 
14 atopic / 5 non-atopic 
5 yes/ 14 no 
7 
13 
9 
12 
13 
2 
3 
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Table 6-2. Maximum % Fall in PEFR from Pre-Exercise Baseline on the Initial Screening Day 
for Patients Showing a LAR 
Pat.No. Order Group Baseline PEFR (L/min) EAR (max % fall) LAR (max % fall) 
1 
2+ 
3 
4+ 
5 
6 
7 
8 
9 
11 
12 
13+ 
15 
34+ 
35+ 
36 
37 
38 
39 
2 
1 
1 
2 
1 
2 
2 
1 
2 
1 
2 
2 
1 
1 
2 
2 
1 
2 
1 
375 
425 
375 
290 
285 
390 
255 
480 
495 
410 
300 
400 
425 
320 
400 
285 
295 
355 
395 
14.7 
52.9 
6.7 
3.5 
40.4 
71.8 
37.3 
10.4 
49.5 
43.9 
13.3 
55.0 
41.2 
6.3 
0.0 
36.8 
39.0 
18.3 
72.2 
33.3 
20.0 
33.3 
37.9 
43.9 
28.2 
49.0 
20.8 
19.2 
41.5 
30.0 
72.5 
27.1 
37.5 
21.3 
47.4 
52.5 
18.3 
41.8 
Order group: 1 = nedocromil sodium/placebo 
2 = placebo/nedocromil sodium 
+ No values have been excluded following bronchodilator use by these patients 
115 
Table 6-3: Analysis of Absolute Decreases in PEFR (L/min) from Pre-Exercise Baseline Mean (sample size) 
at Each Time Point Post-Exercise Challenge: - EAR (1-60 minutes) 
Absolute Decrease from Pre-Exercise Baseline Mean at Each Mean Maximum 
Treatment Pre-Exercise Time Point (Minutes) Post-Exercise Challenge % Fall from 
Baseline Mean Pre-Exercise AUC 
1 3 5 7 10 15 30 60 Baseline 
None 368.8 49.2 80.8 110.4 114.6 122.1 126.3 143.8 115.4 47.4 7434.6 
(Screen) (12) (12) (12) (12) (12) (12) (12) (12) (12) (12) (12) 
ι- Nedocromil 370.4 
0 4
 sodium (12) 
Placebo 382.3 
(12) 
Significance 
of Treatment NS 
Comparison 
-11.3 
(12) 
26.9 
(12) 
NS 
25.8 
(12) 
60.2 
(12) 
NSf 
24.6 
(12) 
84.0 
(12) 
* 
25.4 
(12) 
95.6 
(12) 
* 
36.7 
(12) 
112.7 
(12) 
• 
23.3 
(12) 
106.9 
(12) 
* 
14.2 
(12) 
131.5 
(12) 
** 
5.4 
(12) 
90.6 
(12) 
** 
13.2 
(12) 
36.6 
(12) 
*» 
933.1 
(12) 
6391.0 
(12) 
** 
Noie: results of the screen day challenge are shown for reference only 
NSp>0.05; NS+0.05<p<0.10; * p<0.05; •* p<0.01 
Table 6-4: Analysis of Absolute Decreases in PEFR (LImin) from Pre-Exercise Baseline Mean (sample size) 
SL Each Time Paini 
Treatment Pre-Exercise 
Baseline Mean 
None 
(Screen) 
Nedocromil 
sodium 
Placebo 
Significance 
of Treauneni 
Comparison 
369.2 
(18) 
370.3 
(18) 
374.3 
(18) 
t MS 
¡ Post-Exercise Challenge: - LAR í4-n hoursì 
Absolute Decrease from Pre-Exercise Baseline Mean at 
Time Point (Hours) Post-Exercise Challenge 
4 5 6 7 8 9 10 11 
55.0 
(18) 
-4.4 
(18) 
43.8 
(18) 
«* 
69.7 
(18) 
-0.6 
(18) 
52.4 
(18) 
NSf 
67.1 
(17) 
8.5 
(17) 
61.5 
(17) 
* 
66.5 
(17) 
7.4 
(17) 
53.8 
(17) 
NS 
80.6 
(17) 
7.1 
( Π ) 
52.9 
(17) 
* 
99.7 
(17) 
22.4 
( Π ) 
52.1 
(17) 
NS 
73.5 
(17) 
24.4 
( Π ) 
50.3 
(17) 
NS 
69.4 
(17) 
19.1 
(17) 
59.1 
(17) 
# 
Each 
12 
74.7 
(17) 
11.8 
( Π ) 
52.1 
(17) 
NSt 
Mean Maximum 
% Fall from 
Pre-Exercise 
13 Baseline 
84.1 
(17) 
23.4 
(16) 
52.8 
(16) 
NS 
35.3 
(18) 
12.4 
(18) 
25.8 
(18) 
** 
AUC 
687.2 
(16) 
116.4 
(16) 
484.7 
(16) 
NSf 
Note: results of the screen day challenge are shown for reference only 
NSp>0.05; NS+0.05<p<0.10; * p<0.05; ** p<0.01 
Table 6-5: Maximum Percentaye Fall in PEFR from Pre-Exercise Baseline 
Maximum % Fall in PEFR from Pre-Exercise Baselme 
Pat EAR (1-60 mmutes) LAR (4-13 hours) . 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
11 
12 
13 
15 
34 
35 
36 
37 
38 
39 
Mean 
±S> 
Sample 
size 
Screen 
-
54.0 
-
-
40.4 
71.8 
37.3 
-
49.5 
43.9 
. 
55.0 
41.2 
-
-
36.8 
39.0 
18.3 
72.2 
46.6 
±15.2 
12 
Active 
-
26.7 
-
-
5.7 
5.1 
16.7 
-
26.9 
4.2 
. 
15.2 
22.2 
-
-
0.0 
1.8 
2.7 
30.7 
13.2 
±11.2 
12 
: Placebo 
-
54.3 
-
. 
40.4 
81.6 
16.0 
-
47.9 
3.8 
-
60.6 
41.9 
-
-
29.0 
7.0 
0.6 
56.2 
36.6 
±25.6 
12 
Screen 
33.3 
21.8 
33.3 
37.9 
43.9 
28.2 
49.0 
20.8 
19.2 
41.5 
30.0 
72.5 
27.1 
. 
21.3 
47.4 
39.0 
18.3 
41.8 
34.8 
±13.7 
18 
Active 
15.0 
8.9 
12.7 
-1.4 
5.7 
-2.6 
41.7 
6.8 
14.0 
1.4 
29.8 
30.4 
22.2 
. 
7.8 
20.0 
-7.1 
-16.0 
34.7 
12.4 
±15.3 
18 
Placebo 
14.3 
23.9 
21.6 
-11.1 
40.4 
34.7 
20.0 
10.1 
10.4 
62.0 
22.2 
54.5 
32.6 
-
15.0 
39.5 
14.7 
14.8 
44.5 
25.8 
±17.9 
18 
Table 6-6: EAR and LAR PEFR Values Related to % Predicted Nonnal Values 
Pat Predicted Pre-Exercise Baseline PEFR as % Pred EAR lowest PEFR as % Pred LAR lowest PEFR as % Pred 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
11 
12 
13 
15 
34 
35 
36 
37 
38 
39 
PhbK 
430 
439 
418 
440 
391 
589 
437 
429 
427 
378 
403 
463 
625 
477 
519 
362 
365 
497 
530 
Screen 
87.2 
99.1 
89.7 
65.9 
72 9 
66 2 
58.4 
111.9 
115.9 
108.5 
74.4 
86.4 
68.0 
67.1 
77.1 
78.7 
80.8 
71.4 
74.5 
Placebo 
81.4 
104.8 
88.5 
71.6 
72 9 
83 2 
57.2 
103.7 
112.4 
104.5 
67.0 
71.3 
68.8 
68.1 
77.1 
105.0 
88.4 
85.0 
64.6 
Active 
93.0 
102.5 
84.9 
80.7 
67 8 
66 2 
54.9 
102.6 
108.9 
93.9 
70.7 
99.4 
57.6 
73.4 
74.2 
82.9 
76.7 
75.5 
95.3 
Screen 
74.4 
45.6 
83.7 
63.6 
43.5 
18.7 
36.6 
100.2 
58.5 
60.8 
64.5 
38.9 
40.0 
62.9 
77.1 
49.7 
49.3 
58.4 
20.8 
Placebo 
81.4 
47.8 
78.9 
68.2 
43.5 
15.3 
48.1 
90.9 
58.5 
100.5 
62.0 
28.1 
40.0 
71.3 
79.0 
74.6 
82.2 
84.5 
28.3 
Active 
97.7 
75.2 
78.9 
47.7 
63.9 
62.8 
45.8 
93.2 
79.6 
89.9 
59.6 
84.2 
44.8 
67.1 
77.1 
82.9 
75.3 
73.4 
66.0 
Screen 
58.1 
77.4 
59.8 
40.9 
40.9 
47.5 
29.7 
88.6 
93.7 
63.5 
52.1 
23.8 
49.6 
-
60.7 
41.4 
38.4 
58.4 
43.4 
Placebo 
69.8 
79.7 
69.4 
79.5 
43.5 
54.3 
45.8 
93.2 
100.7 
39.7 
52.1 
32.4 
46.4 
52.4 
65.5 
63.5 
95.9 
72.4 
35.8 
Active 
79.1 
93.4 
74.2 
81.8 
63.9 
67.9 
32.0 
95.6 
93.7 
92.6 
49.6 
69.1 
44.8 
68.4 
66.3 
54.8 
87.5 
62.3 
Mean 453 82 83 82 55 62 72 54 63 70 
-•Φ ±72 ±17 ±17 ±16 ±21 ±24 ±15 ±19 ±21 ±18 
Table 6-7. Maximum % Fall in PEFR fLARi from Pre-Exercise Baseline 
and a Comparison of the Maximum % Fall in Relation to the 
Control PEFR Value at the Corresponding 'CInclctime' 
Pat. 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
11 
12 
13 
15 
34 
35 
36 
37 
38 
LAR % Fall from 
Pre-Exercise Baseline 
Screen 
33.3 
30.0 
33.3 
37.9 
43.9 
28.2 
49.0 
20.8 
19.2 
41.5 
30.0 
72.5 
27.1 
-
21.3 
47.4 
39.0 
18.3 
Placebo 
14.3 
23.9 
21.6 
-11.1 
40.4 
34.7 
20.0 
10.1 
10.4 
62.0 
22.2 
54.5 
32.6 
-
15.0 
39.5 
14.7 
14.8 
Active 
15.0 
8.9 
12.7 
-1.4 
5.7 
-2.6 
41.7 
6.8 
14.0 
1.4 
29.8 
30.4 
22.2 
-
7.8 
20.0 
-7.1 
-16.0 
LAR % Fall from 
No-Exercise 'Clocktime' Baseline 
Screen 
34.2 
19.0 
10.7 
45.5 
20.0 
24.3 
0.0 
11.6 
2.4 
20.0 
12.5 
72.5 
16.2 
-
7.4 
16.7 
40.0 
22.7 
Placebo 
21.1 
-20.7 
-1.8 
0.0 
15.0 
-3.2 
0.0 
9.1 
4.4 
50.0 
6.0 
62.5 
19.4 
-
0.0 
-15.0 
8.3 
-2.9 
Active 
10.5 
2.4 
-24.0 
-9.1 
-8.7 
2.4 
-7.7 
0.0 
10.1 
-11.1 
25.9 
14.7 
24.3 
-
-18.3 
-33.3 
0.0 
-17.6 
39 41.8 44.5 34.7 36.1 56.8 10.8 
Mean 35.3 25.8 12.4 22.9 11.6 -1.6 
±Φ ±13.4 ±17.9 ±15.3 ±17.6 ±23.2 ±16.2 
CHAPTER? 
SUMMARY AND CONCLUSIONS 
7-1. SUMMARY 
7-2. CONCLUSIONS 
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7-1. Summary 
Chapter 1 presented a general introduction and an outline of the objectives of the studies 
presented in this thesis. The late asthmatic reaction (LAR) after exercise challenge remains a 
controversial issue. A number of studies in the past have put some evidence for the occurrence 
of a LAR after exercise challenge. This response after exercise challenge is usually present 3-13 
hours after exercise challenge and the decline in peak expiratory flow rate (PEFR) is easily 
monitored by a mini-Wright peak flow meter. The objectives of the various studies was first to 
examine the existence and prevalence of the LAR after exercise challenge, and if so to define 
this reaction properly; second to examine the reproducibility of this reaction and third to look at 
the protective effect of nedocromil sodium on the EAR and LAR after exercise challenge. 
Fourth the pathofysiological mechanisms behind the LAR after EC were investigated. 
Chapter 2 dealed with the prevalence of the LAR and early asthmatic reaction (EAR) after 
exercise challenge. There is a discussion going on about the existence of a LAR after exercise 
challenge. The controversy in the literature is whether the LAR after exercise challenge does 
occur, and if so what is the frequency of it and to which value should the PEFR after exercise 
challenge be related to. In this study the post-exercise decrease in PEFR was compared with the 
corresponding clocktime PEFR on a control day. Patients were randomized for a control day 
and an exercise day and PEFR was recorded at t=0 (pre-exercise PEFR) and 1, 3, 5,7,10,15 
and 30 minutes, and then hourly during the 13 h after the end of the exercise challenge. The 
control day was monitored in the same way as the exercise day with the only difference that no 
exercise test took place. 
A considerable number of late responses was found: out of 86 patients with reversible 
airflow limitation 19% had a LAR after exercise challenge when a PEFR fall > 20% compared 
to corresponding clocktime on a control day was used as a definition. Of the examined patients 
38% had a LAR after exercise challenge when a PEFR fall £ 10% compared to corresponding 
clocktime on a control day was used as a definition. The late response after exercise challenge 
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can occur as an isolated or as a dual reaction. The dual reaction (LAR + EAR) took place in 13 
out of the 86 patients studied. Despite the use of oral and inhaled steroids a LAR after exercise 
challenge could occur. Concluded is that one should only speak of a LAR after exercise 
challenge when the diumal post-exercise PEFR rhythm had been compared with a day without 
exercise. 
In chapter 3 the distinction between true and pseudo LARs after exercise challenge was made, 
based on fluctuations of the PEFP. on control days in relation to days with exercise challenge. 
The normal variability of the PEFR was identified in another group of asthmatics who did not 
undergo exercise challenge. Twenty-one patients recorded PEFR on two control days without 
performing exercise. There was no difference between both control days when PEFR at one 
hour was compared to baseline PEFR and when PEFR at 3-13 hours was compared to baseline 
PEFR. After analyzing variation coefficients of baseline PEFR on a control- and exercise day, 
PEFR was not allowed to differ more than 15.3% in the same patient, when comparing 
exercise- and control day for the late fall in PEFR in this study. In 17 out of 81 patients with 
reversible airflow limitation a late asthmatic reaction after exercise challenge was present, when 
PEFR fall was £20% compared to baseline PEFR value. In 8 out of the 17 patients a real late 
asthmatic reaction to exercise challenge was present on at least 3 successive time points and a 
PEFR fall £20% in comparison with corresponding clocktime on a control day. 
Based on the above mentioned observations it was deduced that a LAR after exercise 
challenge is best described by a 20% or greater fall in PEFR on 3 successive time points in 
comparison with corresponding clocktime on a control day. Isolated declines in PEFR on three 
not successive time points or other falls in PEFR not related to corresponding clocktime on a 
control day were termed pseudo LARs. 
This study confirms the presence of late asthmatic responses after exercise challenge. 
The majority of the patients tested were receiving either or both inhaled and systemic 
glucocorticosteroids. These agents have been known to inhibit not only late asthmatic responses 
after antigen but they may also alter the variability of airway calibre. This underscored the 
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presence of a LAR after exercise challenge. Graphic illustration of airway responses following 
exercises could facilitate the detection of late asthmatic responses. 
In chapter 4 the reproducibility of the LAR after exercise challenge was studied. The examined 
asthmatic patients performed an exercise test and they recorded thereafter their PEFR as well as 
on a control day. When a LAR after exercise challenge was present, which was defined as a 
PEFR fall S 20% on three or more time points 3-13 hours after exercise challenge compared to 
corresponding clocktime on a control day, they performed a second exercise challenge and 
control day. We investigated whether this reaction was reproducible when patients were 
rechallenged 21-150 days after the first exercise challenge. Eighty three hospitalized patients 
with reversible airflow limitation were challenged with exercise. The patients were examined 
according to a standardized protocol which comprised eight minutes bicycling at 90% of 
predicted heart-rate. 
Eleven patients (13.3%) had a PEFR fall greater than 20% 3-13 hours after exercise. 
Those patients who showed a late asthmatic response after exercise challenge were rechallenged 
in order to study the reproducibility of this reaction. Eight of those patients (73%) showed a 
reproducible late bronchoconstrictive reaction after exercise challenge when compared with a 
new control day. Areas under the curve 3-13 hours after the first and second exercise challenge 
in addition showed a good reproducibility. The presented study clearly supported existing 
evidence for the occurrence of a LAR after exercise challenge and its reproducibility when very 
strict criteria as mentioned above were applied. Using these criteria it could even be shown that 
the LAR after exercise challenge did occur after a period of 11 months. Since the therapy 
regimen for the patients was kept unaltered between the two challenge occasions it denied the 
fact that the LAR after exercise challenge could be due to medication withdrawal. Furthermore, 
it extended the evidence that the LAR after exercise challenge was not a coincidence of a stable 
control day and an unstable exercise challenge day, since both were registered on two different 
occasions with an in between time period of 21-150 days. In this selected group of asthmatic 
patients the LAR after exercise challenge pointed out to be reproducible in 73% of the cases. 
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From the presented data it was clear that, when strict criteria were applied for the LAR after 
exercise challenge, it was almost as reproducible as the LAR after antigen challenge. Although 
the LAR after exercise challenge in itself was reproducible, the time points at which the maximal 
PEFR fall occurred were not reproducible 
In chapter 5 an investigation was done in order to try to clarify the pathophysiological 
mechanisms behind the LAR after exercise challenge. A reproducible LAR after exercise 
challenge was defined as a PEFR fall £20% on three or more time points 3-13 hours after 
exercise challenge compared to corresponding clocktime on a control day after the first and 
second exercise challenge, (as is outlined in chapter 4.) In 9 patients with a reproducible LAR 
after exercise challenge a bronchial provocation test with histamine was done before exercise 
challenge, after one hour, 24, and 48 hours after exercise challenge. Before exercise challenge 
an iv catheter was placed in an antebrachial vene for the investigation of blood eosinophiles, 
neutrophiles, basophiles as well as serum eosinophil cationic protein levels and serum histamine 
levels. Blood was collected before exercise challenge, 3 and 15 minutes after exercise challenge 
and 3, 6,9, 24,48, hours after exercise challenge. Three patients with a reproducible negative 
LAR after exercise challenge underwent the same investigation. 
It appeared that the histamine threshold did not differ significantly in the patients with a 
LAR after exercise challenge; neither there was a significant difference when the positive LAR 
group was compared with the group without a LAR after exercise challenge. Also the peripheral 
blood cells measured after exercise challenge showed no significant difference in each of the 
patients with a LAR after exercise challenge. This was also the case for serum eosinophil 
cationic protein levels and serum histamine levels. When the positive LAR group was compared 
with the negative LAR group there was no difference which could elucidate the mechanism 
behind the LAR after exercise challenge. It was therefore concluded from this study that if an 
inflammatory component was involved in the LAR after exercise challenge it was not reflected 
by the here measured parameters. It was concluded that more research is necessary to clarify the 
mechanism behind the LAR after exercise challenge. Perhaps the methods used in this study 
125 
were not sensitive enough to detect the role of inflammation and bronchial hyperreactivity in 
patients with a LAR after exercise challenge. 
In chapter 6 the protective effect of nedocromil sodium on the LAR after exercise challenge was 
discussed. In a double-blind placebo-controlled crossover design study the effect of nedocromil 
sodium on the EAR and LAR after exercise challenge with particular emphasis on the LAR, was 
evaluated. A positive asthmatic reaction was defined as a PEFR fall ä 15%. 
After exercise challenge out of a group of 86 patients with reversible airflow limitation, 33 
patients experienced an EAR whereas 19 patients experienced a LAR 3-13 hours after 
challenge. These numbers were based on comparison of the PEFR fall with the pre-exercise 
value. In case the PEFR fall was compared with the corresponding clocktime value on a control 
day without exercise challenge, only 10 out of the 19 patients experienced a LAR. The 19 
patients who showed a positive LAR after exercise challenge compared to pre-exercise PEFR 
value were rechallenged twice after pretreatment with either placebo or 4 mg nedocromil sodium 
in a randomized order. It could be shown that nedocromil sodium has a significant protective 
effect in comparison with placebo on both the EAR and LAR after exercise challenge. Although 
the mode of action of nedocromil sodium remains unclear, the study showed that patients with 
reversible airflow limitation experiencing EAR and LAR after exercise benefit bom nedocromil 
sodium therapy. 
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7-2. Conclusions 
l.In patients with bronchial asthma and COPD a late asthmatic reaction (LAR) after exercise 
challenge occurs. The best method to detect a LAR after exercise challenge is when the maximal 
post-exercise fall in peak expiratory flow rate (PEFR) is compared with corresponding 
clocktime PEFR value on a day without exercise. 
2.The LAR after exercise challenge is best described by a 20% or greater reduction in PEFR on 
three successive time points as compared to to corresponding clocktime on a control day. 
Isolated or other declines in PEFR are termed pseudo LARs. 
3.The reproducibility of the LAR after exercise challenge is 73 %. 
4.Histamine thresholds do not differ significantly in patients with a LAR after exercise 
challenge during the course of the LAR. Also peripheral inflammatory blood cells measured 
after exercise challenge showed no significant difference in each of the patients with a LAR after 
exercise challenge as well as serum eosinophil cationic protein levels and serum histamine 
levels. 
S.Nedocromil sodium demonstrates a significant protective effect on both the EAR and LAR 
after exercise challenge. 
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Samenvatting 
Hoofdstuk 1 bevatte een algemene inleiding over de late astmatische reactie (LAR) en het doel 
van de studies die in dit proefschrift werden behandeld. De LAR na inspanningsprovocatie is 
een controversieel gegeven, hoewel enige studies in het verleden bewijzen hebben geleverd 
voor het bestaan van deze reaktie. De LAR na inspanning is gewoonlijk aanwezig 3-13 uur na 
inspanning. De vermindering in peak-flow is eenvoudig te volgen door middel van een mini-
Wright peak-flow-meter. Het doel van de verschillende studies, die in dit proefschrift zijn 
vermeld, was om eerst het bestaan van de LAR na inspanning aan te tonen en de prevalentie 
ervan vast te stellen. Verder werd aandacht besteed aan de moeilijkheid om de LAR na 
inspanning te definieren. Ten tweede werd de reproduceerbaarheid van de LAR na inspanning 
onderzocht. Ten derde werd het beschermende effect van nedocromil natrium op de EAR en 
LAR na inspannings-provokade vastgesteld en ten vierde werd op mogelijke pathofysiologische 
mechanismen van de LAR na insparmings-provokatie ingegaan. 
Hoofdstuk 2 behandelde de frequentie van voorkomen van de LAR en de vroege astmatische 
reactie (EAR) na inspanning. Uit literatuur onderzoek blijkt dat er twijfel bestaat aan het bestaan 
van de LAR na inspanning. Als deze bestaat is het onduidelijk wat de frequentie hiervan is en 
op welke referentiewaarden de peak-flow daling na inspanning gericht moet worden. In deze 
studie werd de vermindering in peak-flow na inspanning vergeleken met een peak-flow meting 
op hetzelfde tijdstip tijdens een controledag. Patiënten werden willekeurig verdeeld om op een 
controledag en een inspanningsdag de peak-flow bij te houden. De peak-flow werd gemeten op 
tijdstip t=0 (uitgangspeak-flow) en op 1, 3, 5, 7, 10, 15 en 30 minuten en vervolgens elk uur 
gedurende de daarop volgende 13 uur na inspanning. Op de controledag werd de peak-flow 
bijgehouden op dezelfde manier alleen gedurende elk uur tot 13 uur na 09.00 uur, met het 
verschil dat er geen inspanning plaats vond. 
Van de 86 patiënten met CARA had 19% een LAR na inspanning, als de peak-flow 
daling gedefinieerd werd als een >20% daling ten opzichte van de overeenkomstige meting op 
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hetzelfde tijdstip tijdens een controledag. Achtendertig procent van de onderzochte patiënten had 
een LAR na inspanning als de peak-flow-daling gedefinieerd werd als >10% daling vergeleken 
met de overeenkomstige meting op hetzelfde tijdstip tijdens een controledag. De LAR na 
inspanning kan optreden als een geïsoleerde of een gecombineerde reactie. De gecombineerde 
reactie (LAR + EAR) was bij 13 van de 86 onderzochte patiënten aanwezig. Ondanks het 
gebruik van orale- en inhalatiesteroïden bleek zich een LAR na inspanning te ontwikkelen. De 
conclusie van deze studie was, dat men alleen van een LAR na inspanning kon spreken als de 
peak-flow op de inspanningsdag werd gerelateerd aan die op een controledag waarop geen 
inspanning werd verricht. 
In hoofdstuk 3 werd er onderscheid gemaakt tussen echte en pseudo LAR's na inspanning. Dit 
onderscheid was gebaseerd op fluctuaties van de peak-flow op controledagen vergeleken met 
fluctuaties van de peak-flow op dagen met inspanning. De normale variatie van de peak-flow 
werd vastgesteld in een andere groep astmapatiënten die geen inspanning verrichten. 
Eenentwintig patiënten hielden peak-flow-metingen bij op twee dagen zonder inspanning te 
verrichten. Er werd geen verschil gevonden tussen beide controledagen als de peak-flow na één 
uur vergeleken werd met de eerste peak-flow meting op die dag (uitgangs-peak-flow meting) en 
als de peak-flow na 3-13 uur vergeleken werd met de eerste peak-flow meting. Na analyse van 
variatiecoëfficiënten van uitgangs-peak-flow-waarden van patiënten die hun peak-flow-waarde 
bijhielden op een controle- en inspanningsdag, werd besloten, na statistische analyse, de peak-
flow niet méér te laten verschillen dan 15,3% bij dezelfde patiënt, als inspannings- en 
controledag vergeleken werden met de daling in peak-flow in deze studie. 
Bij 17 van de 81 patiënten met reversibele luchtwegvernauwing was een LAR na 
inspanning aanwezig indien het criterium aangehouden werd van een peak-flow-daling >20% 
vergeleken werd met de uitgangs-peak-flow-waarden. Bij 8 van de 17 patiënten was een "echte" 
LAR na inspanning aanwezig met een peak-flow-daling £20% op tenminste drie opeenvolgende 
tijdstippen. Bovendien was er een peak-flow-daling £20% vergeleken met de peak-flow-
waaiden op de corresponderende tijdstippen van de controledag. Gebaseerd op bovenstaande 
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observaties werd geconcludeerd dat een LAR na inspanning beter beschreven kan worden door 
een daling in peak-flow van 20% of meer op drie opeenvolgende tijdstippen, zowel vergeleken 
met de uitgangs-peak-flow als met de peak-flow-waarde van het corresponderende tijdstip op 
een controledag. Andere dalingen in peak-flow-sterkte, al of niet geïsoleerd, werden in deze 
studie pseudo LAR's genoemd. 
Deze studie bevestigde het bestaan van een LAR na inspanning. Het merendeel van de 
patiënten die onderzocht werden, gebruikte inhalatie- en/of systemische glucocorticosteroïden. 
Deze medicamenten hebben de eigenschap dat zij de late reactie na antigeen kunnen remmen, 
echter ook de variabiliteit van het lumen van de luchtweg kunnen verminderen. Dit had invloed 
op het aantal LAR's dat gevonden werd. Luchtwegreacties na inspanning konden ten aanzien 
van de opsporing van een LAR na inspanning gemakkelijker gezien worden op curven van 
peak-flow-waarden. 
In hoofdstuk 4 werd de reproduceerbaarheid van de LAR na inspanning bestudeerd. De 
onderzochte patiënten met asthma bronchiale hielden door middel van een mini-Wright peak-
flow-meter, de peak-flow bij op een controledag en een dag na een inspanningtest bij. Een 
peak-flow-waarde-daling van ¿20% op drie achtereenvolgende tijdstippen 3-13 uur na 
inspanning op de inspanningsdag als deze vergeleken werden met peak-flow-waarden op 
dezelfde tijdstippen van een controledag werd gedefinieerd als een positieve LAR na 
inspanning. Als een LAR na inspanning aanwezig was, werden zij onderworpen aan een 
tweede inspannings- en controledag. Onderzocht werd of de daling in peak-flow 
reproduceerbaar was, als de patiënten 21-150 dagen na de eerste test voor de tweede maal een 
inspanningstest ondergingen. Drieentachtig CARA-patiënten die opgenomen waren in het 
Nederlands Asthmacentrum Davos werden onderworpen aan een inspanningstest. Zij werden 
onderworpen aan een gestandaardiseerd protocol, hetgeen inhield: acht minuten fietsen bij 90% 
van de voorspelde maximale hanfrequentie. 
Elf patiënten (13.3%) hadden 3-13 uur na inspanning een peak-flow-daling van meer 
dan 20%. Deze patiënten (die een late reactie na inspanning hadden) werden voor een tweede 
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maal onderworpen aan een inspanningstest om de reproduceerbaarheid van deze reactie na te 
gaan. Acht (73%) van deze patiënten vertoonden een reproduceerbare LAR na inspanning 
vergeleken met een nieuwe controledag. Oppervlakten onder de peak-flow-curve 3-13 uur na de 
eente en tweede inspanningstest lieten een goede reproduceerbaarheid zien. 
Deze studie gaf duidelijk een bewijs voor de aanwezigheid van een LAR na inspanning, 
die bovendien reproduceerbaar was als strikte criteria werden toegepast. Van deze criteria 
gebruik makende, kon aangetoond worden dat de LAR zelfs optreedt na een periode van elf 
maanden. Aangezien de therapie voor de patiënten ongewijzigd bleef gedurende de twee 
inspannings- en controledagen, moet het uitgesloten worden geacht dat de LAR na inspanning 
het gevolg kon zijn van medicatie-onthouding. De LAR na inspanning kon geen toevalligheid 
zijn van een stabiele controledag en een instabiele inspanningsdag, aangezien beide 
inspannings-en controledagen geregistreerd werden op twee verschillende dagen met een 
tijdsinterval van 21-150 dagen. In deze geselecteerde groep van CARA-patiënten bewees de 
LAR na inspanning reproduceerbaar te zijn in 73% van de gevallen. De LAR na inspanning 
bleek even reproduceerbaar te zijn als de LAR na antigeen provocatie, als stricte criteria werden 
gehanteerd. Het tijdstip van optreden van de maximale peak-flow-daling na inspanning bleek 
echter niet reproduceerbaar (Alhoewel de LAR na inspanning reproduceerbaar was). 
In hoofdstuk 5 werd een gedeelte van de mogelijke pathofysiologische mechanismen van de 
LAR na inspanning onderzocht. Bij 9 patiënten met een reproduceerbare LAR na inspanning 
zoals beschreven in hoofdstuk 4 (een peak-flow daling ¿20% 3-13 uur na provokatie op 2 
inspannings dagen vergeleken met de peak-flow-waarden op het corresponderende tijdstip van 
de 2 controledagen) werd een bronchusprovocatietest gedaan met histamine voor inspanning, 1 
uur, 24 en 48 uur na inspanning. Voor dat inspanning plaatsvond, werd een intraveneuze 
catheter in een antebrachiale vene geplaatst zowel voor onderzoek van bloed op eosinofielen, 
neutroñelen, basofielen, als voor serum eosinofiel catíonic protein (s-ECP) en serum histamine-
spiegels. Bloed werd verzameld voor inspanning, 3 en 15 minuten na inspanning en 3,6,9,24 
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en 48 uur na inspanning. Een controlegroep van drie patiënten met een reproduceerbare 
negatieve LAR na inspanning onderging dezelfde onderzoeken. 
Het bleek dat de histaminedrempel niet significant verandert was na inspanning en het 
beloop niet anders was dan bij de patiënten met een negatieve LAR na inspanning. Daarnaast 
bleek uit de perifere inflammatoire cellen dat er geen significant verschil bestond in de patiënten 
met een positieve en negatieve LAR na inspanning evenals voor serum eosinofïel cationic 
protein en serum histamine-spiegels. Als ook de totale positieve LAR-groep vergeleken werd 
met de negatieve LAR-groep ten aanzien van bovengenoemde parameters, kon het mechanisme 
van de LAR na inspanning niet opgehelderd worden. 
Derhalve kon uit deze studie geconcludeerd worden dat als een inflammatoire component 
betrokken was bij de LAR na inspanning, dit niet weerspiegeld werd door de in deze studie 
onderzochte parameters. Verder werd geconcludeerd dat nader onderzoek nodig is om het 
mechanisme van de LAR na inspanning op te helderen. Mogelijkerwijs waren de methoden die 
in deze studie gebruikt zijn, niet sensitief genoeg om de rol van inflammatie in bronchiale 
hypeireactiviteit bij patiënten met een LAR na inspanning op te sporen. 
In hoofdstuk 6 werd het beschermende effect van nedocromil natrium op de LAR na inspanning 
onderzocht. In een "double-blind placebo crossover" studie werd het effect van nedocromil 
natrium op de vroege en late reactie na inspanning bestudeerd, met speciale belangstelling ten 
aanzien van de LAR. Een positieve reactie na inspanning werd gedefinieerd als een peak-flow-
daling al5% vergeleken met de uitgangs-peak-flow waarden. 
In een groep van 86 patiënten vertoonden 33 patiënten een EAR, terwijl 19 patiënten een 
LAR na inspanning hadden. Deze getallen weiden gebaseerd op vergelijking van de peak-flow 
daling na inspanning met de uitgangs-peak-flow meting. Als de peak-flow-daling vergeleken 
werd met de peak-flow-waarde op het corresponderende tijdstip van een controledag, hadden 
10 in plaats van 19 patiënten een LAR na inspanning. De 19 patiënten die een positieve LAR na 
inspanning hadden vergeleken met de uitgangs-peak-flow-waarden, werden onderworpen aan 
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een tweede en derde inspanningstest na "at random" voorbehandeling met óf een placebo óf 4 
mg nedocromil natrium. 
Het bleek dat nedocromil natrium een significant beschermend effect had, zowel op de 
EAR als op de LAR na inspanning. Alhoewel de wijze van werking van nedocromil natrium 
onduidelijk blijft, bleek uit deze studie dat patiënten met CARA die een EAR en/of LAR na 
inspanning hadden, baat kunnen hebben bij nedocromil natrium therapie. 
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Conclusies: 
1. Bij patiënten met astma bronchiale en COPD bestaat een LAR na inspanning. De "beste" 
methode om een late reactie na inspanning te onderzoeken is als de maximale daling in peak-
flow vergeleken wordt met de peak-flow-waarde op het corresponderende tijdstip van een 
controledag waarop geen inspanning plaatsvindt 
2. Een LAR na inspanning wordt "het best" beschreven door een ä 20% daling in peak-flow op 
drie aaneensluitende tijdstippen vergeleken met de uitgangs-peak-flow-waarden én 
vergeleken met de peak-flow-waarde op hetzelfde tijdstip van een controledag. Andere 
dalingen in peak-flow op de inspanningsdag worden pseudo LAR's genoemd. 
3. De reproduceerbaarheid van de LAR na inspanning is 73 %. 
4. Histaminedrempels verschillen niet significant bij patiënten met een LAR na inspanning 
gedurende het beloop van de late reactie. Ook de perifeer-inflammatoire cellen, gemeten in 
het bloed van patiënten, laten geen verschil zien bij patiënten met een LAR na inspanning. 
Dit geldt ook voor serum eosinofiel cationic protein en serum histamine. 
5. Nedocromil natrium laat een significant beschermend effect zien op zowel de vroege- als late 
reactie na inspanning. 
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dagelijkse contacten die wij onderhielden. Dr.JGR de Monchy, allergoloog Academisch 
Ziekenhuis Gronongen heeft van afstand en soms van nabij zeer deskundige adviezen gegeven 
betreffende de late reaktie na inspanning hetgeen verwantschap vertoonde met zijn thesis de late 
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zeggen voor hun medewerking, het zijn er te veel om op te noemen. 
Mijn ouders wil ik dank zeggen voor de kans die zij me gaven te gaan studeren. 
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Lieve Ans, de steun die jij me gaf is niet in woorden te omschrijven. Weekeinden en 
avonden gingen vaak op aan onderzoek. Je klaagde nooit als ik weer eens naar het NAD moest 
of veel te laat thuis kwam. Tommy en Maitijn pappa heeft nu weer tijd om te fietsen en te 
schaatsen. 
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CURRICULUM VITAE 
De auteur van dit proefschrift werd op 4 oktober 1954 geboren te Deventer. Hij bezocht de 
Alexander Hegius Scholengemeenschap te Deventer. In 1972 behaalde hij het diploma HBS-B 
en startte hij met de studie Geneeskunde aan de Rijksuniversiteit Utrecht. In 1979 werd het arts-
examen behaald. Hiema vervulde hij gedurende 16 maanden de militaire dienstplicht bij de 
Koninklijke Luchtmacht op de Vliegbasis Twente. In september 1980 begon hij de opleiding tot 
internist in het Diaconessenhuis te Arnhem (opleider dr.C.van Gastel). Na deze 2 jarige 
opleiding werd de vervolg opleiding gevolgd in het Academisch Ziekenhuis Utrecht (opleiders 
:prof.dr.A.Struyvenberg en prof.dr.J.van der Sluys Veer). Op 1 september 1985 vond 
inschrijving als internist in het specialistenregister plaats. Hiema was hij werkzaam op de 
afdeling klinische oncologie van de Dr.Daniel den Hoed Kliniek te Rotterdam (hoofd 
dr.G.Stoter). Sinds 1 mei 1986 is hij als staflid en wmd hoofd medische dienst verbonden aan 
het Nederlands Astmacentmm in Davos, Zwitserland. 
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Stellingen behorende bij het proefschrift 
DE LATE ASTMATCSCHE ΚΕΑΚΉΕ NA INSPANNING. 
B.Speelberg 
1. De late astmatische reactie na inspanning is geen epifenomeen, doch een 
reaktie waarvan de ernst en de gevolgen voor de patient niet onderschat moeten 
worden. 
, Dit proefschrift 
2. De beste manier om het bestaan van een late astmatische reaktie na inspanning 
aan te tonen, is het beloop van de peak flow op een dag met 
inspanningsprovocatie te vergelijken met een controledag. 
Dit proefschrift 
3. Nedocromil natrium is een effectief middel bij de behandeling van een 
late reaktie na inspanning. 
4. Multidisciplinaire behandeling in het hooggebergte is een zinvolle aanvulling in 
de behandeling van CARA patiënten, waarvan de behandeling in Nederland niet 
het gewenste effect heeft. 
5. Rugby lokt bij een aantal mensen bekend met inspanningsastma geen aanval 
uit; blijkbaar veroorzaakt dus de aggressieve sport een extra catecholamine-
uitscheiding die beschermend werkt. 
Anderson К, 1985 
6. Astma-aanvallen geprovoceerd door sexuele activiteit ("sexercise induced asthma ") zijn 
niet zeldzaam en worden niet door de fysieke activiteit veroorzaakt, maar door angst, 
opwinding, emoties en hyperventilatie. 
Picado S, 1987 
7. Een dalend haemoglobine gehalte in het bloed met fragmentocyten in de 
bloeduitstrijk bij patiënten die met chemotherapie behandeld worden voor een 
gemetastaseerd carcinoom, moet de arts doen denken aan een micro-
angiopathische haemolythische aneamie. 
Speelberg B, e.a. NTvG 1986; 130: 2186-88. 
8. In abetalipoproteinemie is er een posttranslatie defect in de synthese van 
apoproteine B-IOO. 
Dullaart RPF, Speelberg B, e.a. J Clin Invest 1986:78: 1397-
1404 
9. Plasmacytomen kunnen bij een extramedullaiie lokalisatie aanleiding geven tot 
obstruktie icterus. 
Speelberg B, e.a.Neth J Med 1985; 28: 291-294 
10. De stapeling van tnacylglycerol in patiënten met vetlever wordt niet veroorzaakt 
door een toegenomen aktiviteit van diacylglycerolacyltransferase, maar door een 
relatief tekort aan phospholipiden. 
Speelberg B, e.a. Eur J Clin Invest 1985; 15: A8 
11. Slapen is geen geringe kunst :men moet er een hele dag voor wakker blijven. 
Friedrich Nietzsche 
12. Een geleerde is een persoon die alles weet van wat anderen niet weten, maar 
niets weet van wat anderen weten. 
Albert Einstein 
13. De enige methode om gezond te blijven is te eten wat je niet wil, te drinken wat 
je niet lekker vindt en te doen waar je geen zin in hebt. 
Mark Twain 


